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1. Introduction 
The acute-phase response is critical to the body's ability to successfully respond to injury. It 
normally lasts only few days; however, if continued unchecked, the acute phase response 
may contribute to the development of chronic inflammatory states, tissue damage and 
disease. The acute phase response is typically characterized by fever and changes in 
vascular permeability, along with profound changes in the biosynthetic profile of various 
acute phase proteins (APPs) (Hack et al., 1997, Gabay & Kushner, 1999). APPs are an 
evolutionarily conserved family of proteins produced mainly in the liver in response to 
infection and inflammation. In all mammalian species, the synthesis of the APPs is mainly 
regulated by inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1 (IL-1) and 
tumor necrosis factor (TNF). For instance, haptoglobin (Hp), C-reactive protein (CRP), 
serum amyloid A (SAA), alpha-1 acid glycoprotein (AGP) and hemopexin are regulated 
mainly by IL-1 or combinations of IL-1 and IL-6, whereas fibrinogen, alpha-1 
antichymotrypsin (ACT) and alpha-1 antitrypsin (AAT) are regulated by IL-6 (Koj, 1985; 
Kushner & Mackiewicz, 1993). Exogenous glucocorticoids can also influence APPs by their 
effect on cytokines. The decreased synthesis of albumin during the inflammatory reaction 
has also been shown to be the result of monocyte/macrophage-derived products, such as IL-
1 (Moshage et al., 1987). The concentration of specific blood APPs varies during 
inflammatory states; increasing or decreasing by at least 25 percent (Kushner et al., 1982). 
Indeed, ceruloplasmin concentrations can increase by 50 percent and CRP and serum 
amyloid A by a 1000-fold (Kushner et al., 1981; Dinarello, 1983; Blackburn, 1994; Gruys et al., 
1994; Ingenbleek & Bernstein, 1999).  
The rise in the plasma concentration of APPs can assist host defense by aiding recognition of 
invading microbes, mobilization of leukocytes into the circulation, and increasing blood 
flow to injured or infected sites. These actions favor the accumulation of effector molecules 
and leukocytes at locally inflamed sites; in essence, they enhance local inflammation and 
antimicrobial defense. Concurrently, the APPs also prevent inflammation in uninvolved 
tissues by neutralizing inflammation-induced molecules (such as cytokines, proteases, and 
oxidants) that enter the bloodstream, by diminishing the proinflammatory responses of 
circulating leukocytes, and by forestalling endothelial activation. 
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A particularly important role for APPs in the establishment of host defense is also suggested 
by the magnitude and rapidity of changes in concentrations of APPs, together with their 
short half-life. This is also supported by the known functional capabilities of the APPs, and 
hence theories as to how they might serve useful purposes in inflammation, healing, or 
adaptation to a noxious stimulus. The functional activities of APPs as well as the 
relationship between protein structure and function are discussed in this chapter.  
2. Diverse functional activities of acute phase proteins (APPs) 
APPs are regarded as both mediators and inhibitors of inflammation operating at multiple 
possible sites.  The classic complement components, many of which are APPs, have central 
proinflammatory roles in immunity. Complement activation leads to chemotaxis, plasma 
protein exudation at inflammatory sites, and opsonization of infectious agents and damaged 
cells. Other APPs such as fibrinogen, plasminogen, tissue plasminogen activator (tPA), 
urokinase and plasminogen activator inhibitor-I (PAI-1) play an active role in tissue repair 
and tissue remodelling (Gabay & Kushner, 1999). APPs also have antiinflammatory actions. 
For example, the antioxidants haptoglobin and hemopexin protect against reactive oxygen 
species, and AAT and ACT both antagonize the activity of proteolytic enzymes 
(Janciauskiene, 2001).  Some metal chelating proteins, such as ceruloplasmin, that binds 
copper, and hemopexin, that binds heme, act more directly against pathogens. Other 
proteins are directly involved in the innate immunity against pathogens. LPS-binding 
protein (LPS-BP), for example, interacts with bacterial lipopolysaccharide (LPS) transferring 
it to CD14, a receptor on the surface of macrophages and B-cells. Following the presentation 
of LPS by LBP, a lipopolysaccharide recognition complex is formed on the membrane via 
the recruitment of a second receptor, Toll Like Receptor 4. These events drive the TLR 
signaling pathway that induces the activation of several inflammatory and immune-
response genes, including pro-inflammatory cytokines (Gutsmann et al., 2001). Some APPs 
might act as protectors against cell death by apoptosis. For example, alpha 1-acid 
glycoprotein (AGP) and AAT have been shown to inhibit the major mediators of apoptosis, 
namely caspase-3 and caspase-7 (Van Molle et al., 1999). There are many diseases where 
induction of specific APPs parallels the degree and evolution of the inflammatory processes, 
hence, elevated APPs can be of diagnostic and prognostic value. The pathogenic role of 
fibrin in thrombosis is well known. CRP has been demonstrated to enhance 
ischemia/reperfusion injury by activating the complement system (Lu et al., 2009). Elevated 
serum values of CRP are known to be associated with an increased risk of human 
atherosclerosis. Ferritin, another APP, is a primary iron-storage protein and often measured 
to assess a patient's iron status. Procalcitonin (PCT), was discovered recently as a marker of 
bacterial infection (Assicot et al., 1993). On the other hand, APPs can be considered as 
putative drugs for the treatment of various inflammatory diseases. Different experimental 
studies have demonstrated how the administration of a specific APP prior to or after the 
initiation of an acute-phase response can switch the pro-inflammatory to the  
anti-inflammatory pathway necessary for the resolution of inflammation. In this regard, 
purified plasma AAT is used for the treatment of emphysema and other diseases in patients 
with inherited AAT deficiency and shows anti-inflammatory and immune modulatory 
effects. 
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3. Multifunctional activities of single APP  
Despite vast pro- and anti-inflammatory properties ascribed to individual APPs, their role 
during infections remains incompletely defined as to the functional advantages acquiring 
from changes in plasma concentrations of the APPs. So far, existing data provide evidence 
that APPs act on a variety of cells involved in the early and late stages of inflammation and 
that their effects are time, concentration and molecular conformation-dependent (Figure 1). 
Many APPs have a duel function; amplifying inflammatory responses when the inciting 
pathogen is present within the host and down-regulating the response when the pathogen 
has been eradicated.  
 
 
Fig. 1. Schematic presentation of factors that may affect activities of APPs. 
3.1 C-reactive protein (CRP) 
C-reactive protein (CRP) is a member of the pentraxin family of proteins, which are serum 
opsonins, which bind to damaged membranes and nuclear autoantigens. CRP has an ability 
to recognize pathogens and to mediate their elimination by recruiting the complement 
system and phagocytic cells, thus making it an important member of the first line of innate 
host defense. The normal concentration in healthy human serum is usually lower than 
10 mg/L, increasing slightly with age. Current research suggests that subjects with elevated 
basal levels of CRP are at an increased risk of diabetes (Pradhan et al., 2001, Dehghan et al., 
2007), hypertension and cardiovascular disease (Koenig et al., 2006). CRP is an ancient 
protein whose biological role appears quite complex. Although, originally CRP was 
suggested to be purely a biomarker, recent studies have pointed that it may in fact be a 
direct mediator of patho-physiological processes.  It is likely that the activity of CRP in 
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humans, either pro- or anti-inflammatory is dependent on the context in which it is acting, 
and thus CRP may be more versatile than previously thought.  
3.1.1 Pro-inflammatory effects of CRP 
CRP displays pro-inflammatory effects by activating the complement system and inducing 
inflammatory cytokines and tissue factor production in monocytes. The binding of 
phosphocholine and the complement pathway component (C1q) by CRP is part of innate 
immunity that activates the classical complement pathway (Gabay & Kushner, 1999; Du 
Clos, 2000). Data on the consumption of complement components and cell lysis have 
indicated that CRP-initiated complement activation is restricted to the formation of the C3 
convertase (Berman et al., 1986). Formation of the alternative pathway amplification 
convertase and of C5 convertases is inhibited by factor H (Mold et al., 1984), which binds 
directly to CRP (Mold et al., 1999). The interactions between CRP and its diverse ligands, 
such as phosphocholine or FcǄ receptors, has the potential to influence a variety of cells and 
pathways with the potential to affect: apoptotic cells (Gershov et al., 2000), damaged cell 
membranes (Volanakis & Wirtz, 1979), phagocytic cells (Ballou & Lozanski, 1992), smooth 
muscle cells (Hattori et al., 2003), and endothelial cells (Pasceri et al., 2000). Experimental 
evidence for the binding of CRP to apoptotic cells was provided recently (Gershov et al., 
2000). The distribution of CRP on the surface of such cells is similar to that of the 
complement membrane attack complex. In addition to the membrane of intact injured cells, 
CRP also binds to membranes and nuclear constituents of necrotic cells. Several nuclear 
constituents, including histones (Du Clos et al., 1988), small nuclear ribonucleoproteins (Du 
Clos, 1989) and ribonucleoprotein particles (Pepys et al., 1994) have been shown to bind 
CRP in a calcium-dependent fashion, and CRP deposition to the nuclei of necrotic cells at 
sites of inflammation has been observed (Gitlin et al., 1977). 
To date, experiments with monocytes have shown that CRP induces the production of 
inflammatory cytokines (IL-1, IL-6, TNFǂ, IL-8) (Ballou & Lozanski, 1992; Xie et al., 2005), 
the generation of reactive oxygen species (Zeller & Sullivan, 1992), leads to increased 
expression of tissue factor (Cermak et al., 1993), and affects cell chemotaxis (Whisler et al., 
1986; Kew et al., 1990). Recently, Hanriot et al. (2008), investigating human monocytes 
exposed to CRP have confirmed the results of earlier studies on CRP-mediated induction of 
expression of numerous proinflammatory cytokine genes (with the exception of TNFǂ) and 
further evidenced increased expression of PAI-2, MCP-1, GRO-ǂ, GRO-ǃ, and the 
chemokine receptors CCR8 and CXCR4.  It has also been demonstrated that isolated from 
serum and recombinant CRP can stimulate expression of the monocytic surface integrin 
CD11b and downregulate that of CD31 antigen (Woollard et al., 2002).  Numerous reports in 
the literature document the role of CRP in atherogenesis. Epidemiological evidence reveals 
an association between elevated plasma CRP and atherosclerosis (Haverkate et al., 1997; 
Ridker et al., 1997; Koenig et al., 1999). Infusion of recombinant CRP in healthy men results 
in the activation of inflammation and coagulation (Bisoendial et al., 2005). In vitro, CRP has 
been shown to exert a direct proinflammatory and proatherosclerotic effect on vascular cells, 
as exemplified by: (1) induction of an increased expression of adhesion molecules, such as 
vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule- 1 (ICAM-1), 
and E-selectin (Pasceri et al., 2000); (2) stimulation of secretion of monocyte chemoattractant 
protein-1 (MCP-1) (Pasceri et al., 2001); and (3) facilitation of macrophage low-density 
lipoprotein (LDL) uptake (Verma et al., 2002a). Transcription of genes encoding the cell 
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adhesion molecules (VCAM-1, ICAM-1, E-selectin) and chemokines is tightly regulated by 
the transcription factor NF-κB, which has been implicated as a key mediator of 
atherosclerosis (Brand et al., 1996; Marumo et al., 1997; Thurberg & Collins, 1998; De Martin 
et al., 2000). However, with regard to the effects of CRP on endothelial cells, published 
studies are somewhat controversial. CRP has been shown to promote production of pro-
angiogenic molecules such as endothelin-1 and IL-6 in human saphenous vein endothelial 
cells (Verma et al., 2002), and activate NF-κB signalling through the CD32 receptor (Liang et 
al., 2006). However, other studies suggested that endothelial cell activation by CRP is due to 
contamination of the commercially obtained protein with LPS and/or sodium azide (Liu et 
al., 2005, Taylor et al., 2005).   
3.1.2 Anti-inflammatory effects of CRP  
3.1.2.1 In vitro 
CRP appears to express anti-inflammatory properties. For example, in monocytic cells CRP 
has been shown to increase the synthesis of interleukin-1-receptor antagonist (IL-1ra), to up-
regulate vascular endothelial growth factor A (VEGF-A) expression (Tilg et al, 1993), to 
increase the release of the anti-inflammatory cytokine IL-10 (Mold et al, 2002; Szalai et al, 
2002) and to repress the synthesis of IFN-Ǆ (Szalai et al, 2002). Furthermore, CRP has been 
reported to display anti-inflammatory effects in monocytes through down-regulation of 
alpha2-macroglobulin expression and up-regulation of liver X receptor ǂ expression 
(Hanriot et al., 2008). CRP was found to bind to a ligand on Leishmania donovani and 
phosphorylcholine-expressing Neisseria meningitides, and hence increase their uptake by 
human phagocytes (Culley et al., 1996, Casey et al., 2008).  Thomas-Rudolph et al (2007) 
have also reported that innate recognition by CRP enhances effective uptake and 
presentation of bacterial antigens through Fc-gamma receptors on dendritic cells and 
stimulates protective adaptive immunity. CRP has been shown to express multiple anti-
inflammatory effects on neutrophils. CRP down-regulates the generation of superoxide by 
activated neutrophils which leads to a significant reduction of intracellular protein 
phosphorylation.  IL-8-, formyl-methionyl-leucyl-phenylalanine (fMLP)-, and the 
complement component C5a-induced chemotactic responses of neutrophils are also found 
to be inhibited by CRP (Zhong et al., 1998). Inhibition of neutrophil chemotactic responses 
by CRP correlates with a reduction of chemotactic peptide-induced p38 kinase activity 
(Heuertz et al., 1999). In addition, CRP has been reported to induce cleavage and shedding 
of L-selectin from the surface of neutrophils, and markedly attenuate the attachment of 
human neutrophils to endothelial cells (Zouki et al., 1997). Finally, CRP has been shown to 
mediate shedding of the membrane-bound IL-6 receptor from neutrophils (Jones et al., 
1999). The combined data on the effects of CRP on neutrophils indicate that this protein can 
limit the inflammatory response.  
3.1.2.2 In vivo 
A variety of studies utilizing exogenous or transgenic CRP have probed the effects of CRP in 
vivo. The ability of CRP to protect mice against bacterial infection by various species has 
been well established. These species include S. pneumoniae (Mold et al., 1981; Szalai et al., 
1995) and Haemophilus influenza (Weiser et al., 1998; Lysenko et al., 2000), which have 
phosphocholine-rich surfaces, and Salmonella enterica serovar Typhimurium, which has no 
known surface phosphocholine, although its cell membrane is known to be rich in another 
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CRP ligand, phosphoethanolamine (Szalai et al., 2000). Protection is presumably mediated 
through CRP binding to phosphocholine or phosphoethanolamine, followed by activation of 
the classical complement pathway. CRP protection of mice infected with S. pneumoniae has 
been shown to require an intact complement system, but does not require interaction with 
FcǄRs (Mold et al., 2002; Szalai et al., 2002). CRP`s protective effects are not limited to 
bacteria. It has been shown to play a protective role in a variety of inflammatory conditions, 
including endotoxin-mediated shock (Mold et al., 2002; Xia et al., 1997). Transgenic mice 
expressing human CRP are resistant to experimental allergic encephalomyelitis (Szalai et al, 
2002). The study by Heuertz and collaborators has demonstrated that pretreatment of 
rabbits with purified human CRP intravenously significantly reduces neutrophil infiltration 
and C5a-induced alveolitis (Heuertz at al., 1993). One of the most commonly studied animal 
models of human systemic lupus erythematosus (SLE) is the female NZB x NZW F mouse 
model (B/W). These mice, as with human SLE patients, develop high levels of 
autoantibodies to nuclear antigens, leading to circulating immune complexes, the renal 
deposition of immune complexes and renal pathology. In this experimental model a single 
injection of human CRP not only markedly delayed the development of proteinuria, but also 
reversed ongoing active nephritis.  The half-life of CRP in mice is only 4 hours (Kushner et 
al, 1978), however, despite the rapid clearance of injected CRP, the downregulation of the 
inflammatory process in the kidney persisted for more than 2 months. This suggests that 
CRP is most likely to be a direct regulator of the inflammation induced by immune complex 
deposition. In support of this B/W mice transgenic for human CRP also show a delayed 
onset of proteinuria and enhanced survival compared with non-transgenic B/W mice 
(Rodriguez et al., 2005). A single injection of CRP both prevents and reverses accelerated 
nephrotoxic nephritis (NTN) in C57BL/6 mice (Rodriguez et al., 2005) indicating that CRP-
induced suppression of immune complex-mediated inflammation is not limited to 
autoimmune nephritis. Protection from NTN by CRP was associated with a decrease in 
inflammatory and pathologic changes in glomeruli and a marked reduction in renal 
expression of IL-1ǃ and other macrophage chemoattractants (Rodriguez et al, 2007).  
3.2 Alpha1-acid glycoprotein (AGP) 
AGP is another example of an APP with multiple biological effects. AGP belongs to the 
lipocalin family, a group of proteins sharing a similar three-dimensional structure capable of 
binding and carrying hydrophobic molecules. The normal range of AGP concentration in 
the serum is 0.5-1.0 g/L, which can be increased several-fold in response to inflammation, 
infection, and systemic tissue injury (Engstrom et al., 2004; Lind et al., 2004). AGP function is 
still unknown; however, this protein is suggested to have a complex role by differentially 
regulating inflammatory responses (Logdberg & Wester, 2000; Fournier et al., 2000). So far, 
the most important function of AGP is linked to its ability to inhibit platelet aggregation 
(Snyder & Coodley, 1976; Costello et al., 1979).  
3.2.1 Pro-inflammatory effects of AGP 
Earlier studies have shown that AGP can activate monocytes, induce T cell proliferation 
(Singh & Fudenberg, 1986) and enhance TNFǂ, IL-1, and IL-6 secretion (Boutten et al., 1992; 
Drenth et al., 1996; Su & Yeh, 1996). More recently it has been demonstrated that AGP 
activates human monocytes to secrete TNFǂ through a tyrosine kinase dependent pathway 
and this can be enhanced in the presence of serum AGP-binding proteins.  Since TNFǂ can 
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also trigger the synthesis and secretion of AGP, the increase in TNFǂ secretion by AGP-
stimulated monocytes may represent a positive feedback of APPs to amplify the 
inflammatory signal (Su et al., 1999). A current study evaluated the effects of bovine AGP on 
neutrophil pro-inflammatory responses, including respiratory burst activity and cytokine 
production, and found that bovine AGP enhanced neutrophil production of IL-8 in a dose-
dependent manner (Rinaldi et al., 2008) 
3.2.2 Anti-inflammatory effects of AGP 
3.2.2.1 In vitro 
AGP has been shown to induce macrophage expression of IL-1ra and soluble TNF receptor, 
which antagonize the activity of IL-1ǃ and TNFǂ, respectively (Tilg et al., 1993, Hochepied 
et al., 2003). Sorensson and colleagues (1999) reported that endothelial barrier functions are 
dependent on the presence of AGP. A number of studies have investigated the effects of 
AGP on neutrophil function. At physiological concentrations, human AGP has inhibitory 
effects on neutrophil chemotactic responses after stimulation with fMLP and the 
complement component C5a (Laine et al., 1990, Vasson et al., 1994). Moreover, it has been 
shown that low doses of AGP promote neutrophil aggregation, while higher doses inhibit 
this response (Laine et al., 1990). Neutrophil respiratory burst activity is also reported to be 
modulated by AGP, and several studies have demonstrated that human AGP can inhibit the 
extracellular release of superoxide anion after activation with opsonized zymosan or 
phorbol 12-myristate,13-acetate (PMA) (Costello et al., 1984; Vasson et al., 1994).  Bovine 
AGP inhibited zymosan-induced neutrophil extracellular release of superoxide anion and 
hydrogen peroxide without affecting the capacity of neutrophils to engulf and kill 
Staphylococcus aureus. Interestingly, AGP exerted its effect on free radical production 
regardless of whether neutrophils were exposed to AGP prior to or after activation (Rinaldi 
et al., 2008). 
3.2.2.2 In vivo 
Several studies have shown that AGP may function as an immune modulator displaying a 
protective effect in different models of shock. In a model of bacterial septic shock, using the 
gram-negative Klebsiella pneumoniae, AGP showed clear protection when given prior to the 
lethal challenge (Fournier et al., 2000). Furthermore, AGP was found to inhibit apoptosis 
and inflammation in murine models, and to induce cAMP-dependent signaling in the 
endothelial cells (Libert et al., 1994; Costello et al., 1979). Using Escherichia coli LPS, an 
initiator of the acute inflammatory response associated with septic shock, Morre DF and 
coworkers (1997) demonstrated that AGP-LPS complexes can activate mouse macrophages 
in vitro and that AGP protects against sepsis. It has also reported that AGP protects mice 
from lethal shock induced by TNFǂ or endotoxin. The protection was observed in both 
normal and in galactosamine-sensitized mice; with optimal desensitization requiring at least 
3 mg of AGP administered 2 hours before the lethal challenge. Under these conditions, 
complete inhibition of all TNF-induced metabolic changes was observed (Libert et al., 1994). 
In another model, AGP has been found to significantly increase survival rate (48 hours) in 
rats with septic peritonitis. This effect was seen when AGP (200 mg/kg i.v.) was given 15 
min prior to and 24 hours after cecal puncture. In a hemorrhagic/hypovolemic shock model 
(including a defined trauma) in rats treated with 200 mg/kg AGP resulted in significantly 
higher values of mean arterial blood pressure, cardiac output and stroke volume when 
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compared to corresponding values obtained after resuscitation with Ringer's solution or- 
intravenous albumin (Muchitsch et al., 1998). In addition, AGP has been found to be 
protective against ischemia reperfusion in kidneys (Daemen et al., 2000). According to the 
results of this study AGP and AAT administered at reperfusion prevented apoptosis at 2 
hours and 24 hours and exerted anti-inflammatory effects, as indicated by reduced renal 
TNF-ǂ expression and neutrophil influx after 24 hours leading to improved renal function. 
Administration of AGP and AAT 2 hours after reperfusion resulted in a similar trend but 
without functional improvement. Moreover ischemia reperfusion elicited an acute phase 
response, as reflected by elevated serum AGP and serum amyloid P (SAP) levels after 24 
hours, and increased hepatic acute phase protein mRNA levels after 18 hours of renal 
reperfusion. Other useful physiological effects of AGP include protection against brain 
edema formation after experimental stroke (Pichler et al., 1999), and injuries after intestinal 
ischemia (Williams et al., 1997).  
3.3 Alpha1-antitrypsin (AAT) 
Alpha1-Antitrypsin (AAT), also referred to as alpha1-proteinase inhibitor or SERPINA1, is 
the prototypical member of the SERPIN (an acronym for serine proteinase inhibitor) family 
of protease inhibitors (Carrell, 1986). The normal plasma concentration of AAT ranges from 
0.9 to 1.75 g/L. AAT is present in all tissues and biological fluids including cerebrospinal 
fluid, saliva, tears, breast milk, semen, urine and bile. Over 100 alleles of AAT have been 
identified to date, of which at least 20 affect either the amount or the function of the AAT 
molecule in vivo (Gooptu & Lomas, 2009). The genes are inherited as co-dominant alleles 
(products of both genes can be found in the circulation). Individuals with plasma AAT 
values below 0.7 g/L are considered to be AAT deficient. In very rare circumstances 
individuals may inherit AAT null alleles which are characterized by very low levels of 
serum AAT. AAT deficiency typically results from point mutations causing a perturbation 
in protein structure and resulting in increased intracellular polymerization and retention in 
the cell of synthesis. Retained AAT polymers in the endoplasmic reticulum of hepatocytes 
can promote liver damage with a variable clinical presentation, from neonatal hepatitis to 
liver cirrhosis and hepatocellular carcinoma in adults. The lack of circulating protein 
predisposes to the development of early-onset COPD (Carrell & Lomas, 1997). AAT 
deficiency has also been associated with a number of other inflammatory diseases, although 
the association is only moderate or weak. These include bronchial asthma, bronchiectasis, 
systemic vasculitis, rheumatoid arthritis, inflammatory bowel diseases, intracranial and 
abdominal aneurysms, arterial dissections, psoriasis, chronic urticaria, mesangiocapillary 
glomerulonephritis, pancreatitis and pancreatic tumors, multiple sclerosis, and other 
occasionally reported conditions (Janciauskiene et al., 2011). 
3.3.1 Anti-inflammatory effects of AAT 
3.3.1.1 In vitro 
It was previously thought that the primary function of AAT was to inhibit  neutrophil 
elastase and proteinase 3 (Gettings, 2002). However, current studies demonstrate that AAT 
is an irreversible inhibitor for kallikreins 7 and 14 (Schapira et al., 1982; Luo et al., 2006), and 
that AAT also inhibits intracellular and cell-surface proteases. Matriptase, a cell surface 
serine protease involved in the activation of epithelial sodium channels, is one such protease 
(Tseng et al., 2008; Janciauskiene et al., 2008). AAT also inhibits the activity of caspase-3, an 
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intracellular cysteine protease which plays an essential role in cell apoptosis (Petrache et al., 
2006). A recent study provides new evidence that AAT inhibits ADAM-17 activity, also 
called TACE (tumor necrosis factor-ǂ-converting enzyme) (Bergin et al, 2010). We recently 
found that AAT inhibits calpain I which is implicated in numerous pathological conditions 
including Alzheimer’s disease, demyelination events of multiple sclerosis, neuronal damage 
after spinal cord injury and hypoxic/ischaemic injury to brain, kidney and heart organs, and 
tumour development and invasion (Al-Omari et al., 2011). The ability of AAT to inhibit 
neutrophil calpain I was related to intracellular entry of AAT via lipid rafts (Subramaniyam 
et al., 2010), a transient rise in intracellular calcium, increase in intracellular cholesterol 
esters, activation of the Rho GTPases, Rac1 and Cdc42, and extracellular signal-regulated 
kinase (ERK1/2). Furthermore, AAT caused a significant inhibition of non-stimulated as 
well as formyl-met-leu-phe (fMLP)-stimulated neutrophil adhesion to fibronectin,  inhibited 
lipopolysaccharide (LPS)-induced IL-8 release and slightly delayed neutrophil apoptosis 
(Al-Omari M et al 2011). Recently, AAT was found to bind to IL-8 and to inhibit IL-8 
interaction with its receptor CXCR1 (Bergin et al., 2010). AAT plays an immunoregulatory 
role, to inhibit neutrophil superoxide production, to enhance insulin-induced mitogenesis in 
various cell lines, and to induce IL-1ra expression (Bucurenci  et al., 1992; She et al., 2000; 
Tilg  et al., 1993). Findings that AAT enhances the synthesis of both transferrin receptor and 
ferritin revealed a role of AAT in iron metabolism (Graziadei et al, 1997). Interestingly, AAT 
has been shown to regulatete heme oxygenase-1 activity in Alzheimer´s disease patients 
(Maes et al., 2006). AAT has also been found to bind to the secreted enteropathogenic 
Escherichia coli proteins (EspB, EspD), thereby reducing their hemolysis of red blood cells 
(Knappstein  et al., 2004). An interaction between AAT and Cryptosporidium parvum (Forney 
et al., 1996), a protozoan parasite, has been shown to inhibit Cryptosporidium parvum 
infection, suggesting a potential role for AAT in cryptosporidiosis. AAT inhibits endotoxin-
stimulated TNF, IL-6, IL-1ǃ and enhances IL-10 expression in human monocytes, 
neutrophils, endothelial cells (Janciauskiene et al., 2007) AAT also expresses a broad anti-
inflammatory profile in gene expression studies on primary human lung microvascular 
endothelial cells, including the suppression of self-induced TNF expression 
(Subramaniyam et al., 2008). Current studies provide further evidence that AAT therapy 
prolongs islet graft survival in transplanted allogeneic diabetic mice (Lewis et al., 2008) and  
show that AAT stimulates insulin secretion and protects ǃ-cells against cytokine-induced 
apoptosis, and these effects of AAT also seem to be mediated through the cAMP pathway 
(Kalis  et al., 2010). In view of these novel findings, it is suggested that AAT may act as an 
anti-inflammatory compound to protect ǃ-cells under immunological attack in type 
1diabetes, and also raise the possibility of a new therapeutic strategy to potentiate insulin 
secretion in type 2 diabetes (Koulmanda  et al., 2008).  
AAT has also been found to express dual, time-dependent effects. Both in vitro and in vivo 
studies have shown that within a short time (2 to 4 hours) AAT amplifies endotoxin (LPS)-
induced pro-inflammatory responses whereas after 18-48 hours AAT significantly inhibits 
LPS-induced TNFǂ, IL-1ǃ and IL-8 expression and release, and enhances IL-10 synthesis 
(Subramaniyam et al., 2010).This finding point to hypothesis that AAT can regulate the 
progression and resolution of the acute-phase reaction in a time-dependent manner. The 
overall view that arises from the current data is that short-term enhancement of LPS-
induced cell activation may be the key mechanism by which the function of AAT is 
accomplished. In keeping with this, several in vitro and in vivo studies have been published 
in which prior initiation of an acute-phase response or administration of a specific APP has 
www.intechopen.com
 
Acute Phase Proteins – Regulation and Functions of Acute Phase Proteins 
 
34
been shown to switch the pro-inflammatory to the anti-inflammatory pathways necessary 
for the resolution of inflammation. 
3.3.1.2 In vivo 
AAT has been found to significantly protect against the lethality induced by TNFǂ or 
endotoxin in mice (Libert et at., 1996). The protection is optimal with a single dose of at least 
300 μg i.p. or 100 μg i.v. given 2 hours before a lethal challenge, either with a low dose of 
TNFǂ in the presence of galactosamine or a higher dose of murine TNF alone. Under 
optimal conditions, the drop in body temperature, the release of liver transaminases, and the 
increase in clotting time are also inhibited. Similarly, Jie and co-workers (2003) have shown 
that pretreatment with AAT (120 mg/kg) can attenuate acute lung injury in rabbits induced 
with endotoxin. The pretreatment of AAT attenuated the deterioration of oxygenation, the 
reduction of compliance and the deterioration of other physiological and biochemical 
parameters mentioned above. In agreement, we currently found that pre-treatment with 
AAT protects mice against LPS-induced lung injury, inhibits LPS-induced pro-inflammatory 
genes and enhances the expression of genes associated with tissue repair and regeneration 
(unpublished data). In another model, Churg  et al, (2001) have demonstrated that at 2 hours 
after dust administration, AAT completely suppressed silica-induced neutrophil influx into 
the lung and macrophage inflammatory protein-2 (MIP-2)/monocyte chemotactic protein-1 
(MCP-1) (neutrophil/macrophage chemoattractant) gene expression, partially suppressed 
nuclear transcription factor -kB (NF-kB) translocation, and increased inhibitor of NF-kB 
(IkB) levels. By 24 hours, PMN influx and connective tissue breakdown measured as lavage 
desmosine or hydroxyproline were still at, or close to, control levels after AAT treatment. In 
the recent study by Lewis e al., (2005), diabetic mice were grafted with allogeneic islets and 
treated with AAT monotherapy. After 14 days of treatment, mice remained normoglycemic 
and islet allografts were functional for up to 120 treatment-free days. After graft removal 
and retransplantation, mice accepted same-strain islets but rejected third-strain islets, thus 
confirming that specific immune tolerance had been induced. Explanted grafts exhibited a 
population of T regulatory cells in transplant sites. Grafts also contained high levels of 
mRNA for foxp3, cytotoxic T lymphocyte antigen-4, TGF-ǃ, IL-10, and IL-1 receptor 
antagonist, but expression of pro-inflammatory mediators was low or absent. After 
implantation of skin allografts, AAT-treated mice had greater numbers of foxp3-positive 
cells in draining lymph nodes compared with control treatment mice. Moreover, dendritic 
cells exhibited an immature phenotype with a decrease in the activation marker CD86. 
Although the number of CD3 transcripts decreased in the DLNs, AAT did not affect IL-2 
activity in vitro. AAT monotherapy provides allografts with anti-inflammatory conditions 
that favor development of antigen-specific T regulatory cells. AAT treatment in humans is 
known to be safe, hence its use during human transplantation may be considered.  
3.3.1.3 Augmentation therapy with AAT in patients 
Based on the protease-antiprotease hypothesis, augmentation therapy was introduced for 
COPD patients with severe (ZZ) AAT deficiency during the 1980s. The major concept 
behind augmentation therapy was that raising the levels of blood and tissue AAT would 
protect the lungs from continuous destruction by proteases, particularly neutrophil elastase. 
Whether this biochemical normalization of AAT levels influences the pathogenic processes 
of COPD is still under debate. However, recent results do suggest that augmentation 
therapy may have beneficial effects including reducing the frequency of lung infections and 
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reducing the rate of decline of lung function. Several non-randomized observational studies 
and one meta analysis on the clinical effectiveness of AAT augmentation treatment showed 
a favorable result regarding lung function (FEV1) in AAT-deficient COPD patients with 
moderate disease undergoing augmentation therapy (Chapman et al, 2009; Stockley et al, 
2009).  
Clinical studies provide evidence that augmentation therapy with AAT reduces the 
incidence of lung infections in patients with AAT deficiency-related emphysema and 
reduces levels of the chemoattractant leukotriene B4. A study by Lieberman and co-workers 
(2000) showed that augmentation therapy with AAT is associated with a marked reduction 
in the frequency of lung infections in the majority of patients. Most patients reported a 
frequency of three to five infections per year before starting AAT therapy, which dropped to 
zero to one infection per year while receiving AAT. In two patients with a prior history of 
continuous lung infections, AAT therapy was associated with the complete absence of 
infection in one patient and with one to two infections per year in the second.  It was also 
reported that aerosolized AAT suppresses bacterial proliferation in a rat model of chronic 
Pseudomonas aeruginosa lung infection (Kueppers et al., 2011) 
Several case reports support the beneficial effects of AAT augmentation therapy in other 
clinical conditions. Two ZZ AAT Spanish sisters with fibromyalgia experienced a rapid, 
progressive, and constant control of their fibromyalgia symptoms during AAT 
augmentation therapy (Blanco et al, 2006). Another report described a 21yr old a ZZ AAT 
female with septal panniculitis which was poorly responsive to dapsone and doxycycline 
treatment, who was successfully treated with intravenous infusion of AAT (Gross et al., 
2008). Recently Chowdhury and collaborators have described a 33-year-old ZZ AAT woman 
with rapidly progressing panniculitis and extensive skin necrosis. Augmentation therapy 
with AAT proved to be life saving (Chrowdhury et al., 2002). Cutaneous vasculitis in a 49-
year-old man with AAT deficiency persisted despite treatment with colchicine, prednisone, 
and antibiotics, but has been effectively controlled with the administration of AAT (Dowd et 
al., 1995). In addition, Griese et al, 2007 examined the effect of 4 weeks of AAT inhalation on 
lung function, protease-antiprotease balance and airway inflammation in Cystic Fibrosis 
(CF) patients. In a prospective, randomised study, 52 CF patients received a daily inhalation 
of 25 mg AAT for 4 weeks targeting their peripheral or bronchial compartment. Inhalation 
of AAT increased AAT levels and decreased the levels of elastase activity, neutrophils, pro-
inflammatory cytokines and the numbers of P. aeruginosa. However, it had no effect on lung 
function. No difference was found between the peripheral and bronchial mode of 
administration. In conclusion, although no effect on lung function was observed, the clear 
reduction of airway inflammation after AAT treatment may precede pulmonary structural 
changes.  
3.4 Other examples of multifunctional APPs 
3.4.1 Haptoglobin (Hp) 
Haptoglobin (Hp) is homologous to the serine proteases of the chymotrypsinogen family 
but has no serine protease activity (Kurosky et al, 1980). Hp exists in two allelic forms in the 
human population, so-called Hp1 and Hp2, the latter one having arisen due to the partial 
duplication of the Hp1 gene. Plasma haptoglobin levels change during life, with Hp levels in 
healthy infants being lower than in healthy adults. In healthy adults, the haptoglobin 
concentration in plasma is 0.38-2.08 g/L (Javid, 1978). Hp, by binding hemoglobin and 
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removing it from the circulation, prevents iron-stimulated formation of oxygen radicals and 
has an important role as an antioxidant (Sadrzadek & Bozorgmehr, 2004). Both in vitro and 
in vivo studies have established that subjects with the Hp1-1 phenotype are more likely to 
resist cellular oxidative stress than those with the Hp2-2 phenotype, with Hp2-1 being 
intermediate (Tseng et al., 2004). Hp has been shown to play an antioxidant/anti-
inflammatory role, to contribute to neutrophil activation, to maintain reverse cholesterol 
transport, to modulate the inhibition of cyclooxygenase and lipooxygenase, and to inhibit 
monocyte and macrophage functions amongst other activities. For instance, Hp inhibited 
respiratory burst activity in neutrophils stimulated with fMLP, arachidonic acid, and 
opsonized zymosan (Oh et al, 1990), inhibited phagocytosis and reduced intracellular 
bactericidal activities of granulocytes (Rossbacher et al, 1999). Moreover, Hp has been found 
to stimulate the formation of prostaglandin E2 in osteoblast-like cells, and to potentiate the 
stimulatory effect of bradykinin and thrombin on PGE2 formation (Frohlander et al, 1991, 
Lerner & Frohlander, 1992). Hp has also been shown to support angiogenesis (Cid et al, 
1993). It has been suggested that the increased levels of Hp found in chronic inflammatory 
conditions may play an important role in tissue repair.  In systemic vasculitis, Hp might 
also compensate for ischemia by promoting the development of collateral vessels. By 
enhancing the Th1 cellular response, Hp establishes Th1-Th2 balance in vitro (Arredouani et 
al., 2003). Hp also inhibits epidermal Langerhans cells in the skin and might have a role in 
preventing T cell–dependent skin disorders (Pagano et al., 1982).  In addition, Hp inhibits 
cathepsin B and L and decreases neutrophil metabolism and antibody production in 
response to inflammation (Oh et al., 1990, Pagano et al., 1982). Iron is one of the essential 
elements for bacterial growth. However, once bound to Hp, hemoglobin and iron are no 
longer available to bacteria that require iron, such as Escherichia coli. Indeed, Eaton and 
collaborators showed that a fatal consequence of intra-peritoneally injected Escherichia coli 
and hemoglobin in rats can be prevented by the administration of Hp (Eaton et al, 1982). In 
the lungs, Hp is synthesized locally and is a major source of antimicrobial activity in the 
mucous layer and alveolar fluid and also has an important role in protecting against 
infection (Yang et al., 1995). Hp-hemoglobin complexes in human plasma inhibit 
endothelium dependent relaxation (Edwards et al, 1986).  
3.4.2 Serum amyloid A (SAA) 
SAA structurally resembles an apolipoprotein, and is mainly transported in association with 
lipoprotein particles, particularly high-density lipoprotein (HDL) (Eriksen & Benditt, 1980). 
The SAA concentration of serum/plasma samples ranges from 1-5 μg/ml. During an acute 
phase response, SAA becomes the main apolipoprotein on HDL, and the displaced Apo-AI 
then becomes available to extract cellular free cholesterol upon interacting with cell-surface 
(Tam et al., 2008). For this reason, and because SAA itself may also extract cholesterol from 
cells (Stonik et al., 2004), it is thought that SAA plays a role in cholesterol metabolism and 
atherosclerosis (Jahangiri et al., 2009). Whether SAA is pro- or anti-atherogenic is not yet 
clear, since putative beneficial effects on cholesterol metabolism may be mitigated by effects 
on inflammation- a known risk factor for atherosclerosis (Libby et al., 2002). Some of the 
effects described for SAA seem to be minimized or abolished by its association with HDL 
(Barter et al, 2004). The very high expression of SAA gives rise to a completely different 
pathological problem: the continuous high expression of SAA is the prerequisite for the 
development of secondary amyloidosis, caused by the conformational change of SAA in an 
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insoluble proteolytic peptide, AA, that deposits as insoluble plaque in major organs (Malle 
& De Beer, 2003). In attempt to understand the biological role of SAA and of its association 
with HDL, it was demonstrated that SAA is able, for instance, to induce leukocyte migration 
(Connolly et al, 2010) and collagenase (Brinckerhoff et al., 1989), and to inhibit the TNFǂ and 
IL-1ǃ- induced hypothalamic PGE2 synthesis (Tilg et al., 1993). Several other SAA activities 
have been described including increasing cleavage of triacylglycerols into glycerol and fatty 
acids on HDL3 by enhancing the activity of secretory phospholipase (Sullivan et al., 2009). 
SAA also directly acts on the cholesterol molecule by decreasing its esterification, and 
increases its uptake by hepatocytes (Steinmetz et al., 1989). Recent studies reveal that serum 
SAA also has a dual role in modulating neutrophil function. SAA induces the differentiation 
of interleukin 10 (IL-10)-secreting neutrophils via signaling dependent on the G protein–
coupled protein FPR2 (formyl peptide receptor 2), but also promotes the interaction of 
neutrophils with invariant natural killer T cells (iNKT cells), restoring T cell proliferation by 
abolishing IL-10 secretion. The final process is dependent on the antigen-presenting 
molecule CD1d and co-stimulatory molecule CD40 and results in less production of IL-10 
and enhanced production of IL-12, thus limiting the suppressive activity of neutrophils (De 
Santo et al., 2010). SAA may affect inflammatory responses by activating its putative 
receptor on neutrophils (FPRL1), leading to increased production of IL-8 (He et al., 2003). 
SAA is also thought to be able to activate TLR2- and TLR4- dependent signaling (Cheng et 
al., 2008). Recent reports suggest that SAA may also play a role in host defense, notably in 
the clearance of Gram-negative bacteria. Shah et al. demonstrated that SAA binds to the 
outer membrane protein A of Escherichia coli, which facilitates bacterial clearance by 
phagocytes (Shah et al., 2006). Such a bactericidal effect of SAA is intriguing in light of the 
reported expression of SAA in intestinal epithelia of rodents and humans, since these cells 
are exposed to many gram-negative bacteria (Berg, 1996). Intestinal epithelial expression of 
SAA protects from colitis by reducing bacterial load (Eckhardt et al., 2010). 
3.5 Importance of the co-ordinated expression and biological activity of APPs 
APP expression represents one of the most important and highly effective mechanisms of 
innate immunity. The wide range of defensive and repair functions fulfilled by APPs not 
only reduces pathologic damage, but also acts as a homeostatic mechanism. On the other 
hand APPs may also play pro-inflammatory roles and produce detrimental effects. 
Importantly, changes in different APPs occur at different rates and to different degrees. 
Ceruloplasmin and the complement components C3 and C4 exhibit relatively modest acute-
phase behaviour (typically about a 50% increases). Concentrations of Hp, AGP, AAT, ACT, 
and fibrinogen ordinarily increase about 2–5-fold. CRP and SAA are normally present in 
only trace amounts, but may exhibit a dramatic increase (1000-fold or more) in individuals 
with severe infections. In contrast, plasma concentrations of negative APPs such as albumin, 
transferrin, transthyretin, alpha-fetoprotein, typically decrease during the acute-phase 
response. These orchestrated alterations in specific APP production during inflammatory 
states are not completely understood. However, the known functional capabilities of many 
of the APPs leads to the logical speculation that specific changes in APP expression serve 
useful purposes in inflammation, healing or adaptation to infection or injury. Moreover, 
current knowledge clearly indicates that during the acute phase reaction a single APP can 
play multiply roles, and that diverse APPs can possess very similar biological activities 
(Figure 3). The combined action of two or more APPs may produce effects that no single 
protein would be able to achieve.  
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For example, diverse APPs like AAT, AGP, Hp, and CRP can have similar anti-
inflammatory and immuno- modulatory roles in experimental models in vitro and in vivo.  
AAT which is an archetypal member of the SERPIN superfamily, a main inhibitor of 
neutrophil elastase, and AGP a member of the lipocalin family, a group of proteins sharing a 
similar three-dimensional structure capable of binding and carrying hydrophobic molecules, 
both inhibit cell apoptosis, inhibit neutrophil chemotaxis and adhesion, inhibit neutrophil 
activation and induce macrophage-derived interleukin-1 receptor antagonist release, and 
protects mice from endotoxin-induced septic shock. Similarly, CRP (opsonin) and Hp 
(hemoglobin binder) inhibit neutrophil activation, including chemotaxis and superoxide 
production and degranulation. Thus, it seems that all these APPs, specifically in neutrophil 
models, show very similar effects. It cannot be excluded that these proteins may have more 
common characteristics and biological effects however the lack of high quality purified 
endotoxin or contaminant-free proteins limits expanding our current understanding. 
A more detailed knowledge of the separate and combined APP functional pathways is 
essential in order to prevent or control development of various pathological conditions as 
well as to develop safe and effective anti-inflammatory therapies. 
 
 
Fig. 3. Diverse APPs express similar anti-inflammatory activities. 
4. APPs structure-function relationship 
Post-translational modifications of proteins can regulate their function by causing changes 
in protein activity, their cellular location and dynamic interaction with other proteins. 
Virtually all proteins function by interacting with other molecules and these interactions can 
have numerous effects on the physical, structural, biochemical and functional properties of 
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proteins. There are also different types of interactions on a protein-protein and protein-
environment level which lead to complex formation, protein degradation, self-assembly or 
other modifications in protein structures, such as oxidation.  The ability to undergo post-
translational conformational changes is crucial for the physiological function of many 
proteins, including APPs. Similarly, such changes could alter both physicochemical and 
functional properties of the proteins with potential unforeseen physiological or pathological 
consequences. Conformational modification may lead to an acquired deficiency of specific 
APP, but also to the generation of new molecular forms with potent biological activities. The 
altered forms of APPs are detected in tissues and fluids recovered from inflammatory sites, 
but the important questions of how they are generated, what their biological activities are, 
and which of them are directly linked to pathological processes and/or may be useful 
markers to characterise disease states, remain to be answered.  Glycosylation is one of the 
most important post-translational modifications of APPs, and has been widely 
acknowledged as one of the most important ways to modulate both protein function and 
lifespan. Glycosylation of APPs which is partially regulated by cytokines may be distinct in 
disease and provide useful disease markers.  
4.1 Glycosylation of APPs 
The N-glycan chains of APP glycoproteins differ in their branching, showing bi-, tri-, and 
tetra-antennary structures. Inflammatory states are usually associated with changes in the 
glycosylation profile of APPs.  It has been demonstrated that there is an increased 
concentration of the conA-reactive microheterogeneous forms of APPs in patients with acute 
inflammation, e.g. acute bacterial infections and burns. Conversely, a shift in the population 
of APPs towards those with a higher content of conA-nonreactive tri- and tetra-antennary 
carbohydrates has been shown in the sera of patients with chronic inflammatory diseases 
(e.g. chronic bacterial infections, rheumatoid arthritis, ankylosing spondylitis) (Hrycaj et al., 
1996; Stibler et al., 1998). An intriguing question is whether the changes in the glycosylation 
profile of APPs might affect their biological activity and/or function. 
4.1.1 AGP 
AGP purified from human plasma consists of a mixture of AGP with different degrees of 
sialylation and glycosylation. It has been demonstrated that microheterogeneity variants of 
AGP differ with regard to their immunomodulatory properties: the conA-nonreactive 
variant of AGP is more effective in modulating of lymphocyte proliferation than conA-
reactive AGP variants. It has also been shown that AGP has an affinity for E-selectin and 
that this affinity can be changed by in vitro fucosylation of AGP (Mackiewicz et al. 1987). 
The highly branched and sialylated form of AGP which is the ligand for cell adhesion 
molecules such as E-selectin and P-selectin, inhibits migration of neutrophils, monocytes 
and T-cells, and modifies complement activity (Hrycaj  et al., 1993). 
Marked changes in AGP glycoforms are observed during acute-phase reactions. The 
changes comprise alterations in branching pattern as revealed by reactivity with 
concanavalin A and the fucose-binding lectin (Elliott et al., 1997). Thus analysis of sialo- and 
asialo-oligosaccharides of AGP as well as its glycoforms is important for understanding the 
biological roles of AGP (Kakehi et al., 2002; Sei et al., 2002). For example, the asialylated 
carbohydrate-deficient variant of AGP appears mainly in sera of patients after acute 
inflammation, infection, burns or other severe tissue damage (Fournier et al., 2000).  
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The expression of a sialyl Lewis x{sLex, NeuAcǂ2-3Galǃ1-4(Fucǂ1-3)GlcNAc-} portion in the 
carbohydrate chains of human AGP molecules has been shown to be of importance in 
inflammation. De Graaf et al. (1993) found a direct relationship between the reactivity of 
human AGP to the fucose-specific binding lectin (Aleuria auranita) and staining of human 
AGP by anti-sLex monoclonal antibody under healthy and disease conditions.  
In a recent study a recombinant form of sialyl Lewisx(sLex)-bearing (sAGP) was 
administered intravenously to rats after 50 min of intestinal ischemia just before 4 h of 
reperfusion. A non-sLex-bearing form of AGP (nsAGP) was used as control. sAGP-treated 
animals had a 62% reduction in remote lung injury, assessed by 125I-albumin permeability, 
compared with those treated with nsAGP. There was a reduction in pulmonary 
myeloperoxidase levels in sAGP-treated rats compared with nsAGP-treated rats. 
Complement-dependent intestinal injury, assessed by 125I-albumin permeability was 
reduced by 28% in animals treated with sAGP compared with those treated with nsAGP 
leading the authors to conclude that sAGP ameliorates both complement- and neutrophil-
mediated injury (Williams et al., 1997). 
The changes in the glycosylation pattern of AGP has been found in patients with ulcerative 
colitis (Ryden et al., 1997), and in patients with various liver diseases (alcoholic liver disease, 
hepatitis B, hepatitis C cirrhosis). For example, hyperfucosylation occurred in all cases of 
liver disease, although the hepatitis B and C samples showed a more significant increase in 
comparison with the others. Additionally N-acetylgalactosamine (GalNAc) was detected in 
the majority of the hepatitis C samples, which was unexpected since this monosaccharide is 
not a usual component of the N-linked oligosaccharide chains (Anderson et al., 2002). 
In the group of Type I diabetic patients with increased urinary albumin excretion, a 
significant increase in alpha3-fucosylation of AGP could be detected. Therefore, the 
increased alpha3-fucosylation of AGP can be used as a putative marker for the development 
of vascular complications in Type I diabetic patients (Poland et al., 2001).  
AGP and its derivatives, prepared by sequential enzymatic cleavage of the carbohydrate 
units, were tested for their nerve-growth-promoting activities with explants of whole dorsal 
root ganglia from chick embryos. The results showed that the AGP derivatives with 
terminal galactose, N-acetylglucosamine, or mannose have marked neurite-promoting 
activities (Liu et al., 1988).  
4.1.2 Other APPs 
AAT has a molecular weight of Mr 52 000, and is 12% carbohydrate by weight.  The AAT 
molecule carries a high negative charge because of sialic acid residues on the three complex 
glycans attached to asparagine residues 46, 83, and 247. Isoelectric focusing of plasma AAT 
leads to the detection of eight bands, which are numbered M1 to M8 (anodal-low pH to 
cathodal-high pH). The bands M4 and M6 are the most abundant of the isoforms, making up 
40% and 34% of the total plasma AAT, respectively, whereas M3 and M5 are present in only 
trace amounts (Mills et al., 2001). Fucosylated AAT was analyzed individually and in 
combination with the currently used marker, alpha-fetoprotein, for the ability to distinguish 
between a diagnosis of cirrhosis and hepatocellular carcinoma (HCC). The levels of 
fucosylated AAT were significantly higher in patients with HCC compared to those with 
cirrhosis (Wang et al., 2009). Remarkably, non-glycosylated AAT showed shorter half life 
and no ability to interact with IL-8 than compared to glycosylated form of AAT (Bergin et 
al., 2010). This suggests an importance of AAT glycosylation for its biological activities. 
www.intechopen.com
 
Acute Phase Proteins: Structure and Function Relationship 
 
41 
ACT (alpha 1-antichymotrypsin), a serine anti-protease with specificity against neutrophil 
cathepsin G, is homologous with AAT, plasminogen activator inhibitor and 
angiotensinogen. ACT is an APP with carbohydrate content 24% of molecular weight. As for 
other glycoproteins, micro-heterogeneity of ACT may be ascribed to differences in 
carbohydrate structure, and indeed different patterns of ACT micro-heterogeneity has been 
shown in different diseases including cancer, heart failure and rheumatoid arthritis (Saldova  
et al., 2008; Kazmierczak et al.,1995; Havenaar et al., 1998).   A low content of terminal 
GlcNac glycans and sialic acid in peripheral ACT has been suggested as a marker of 
progression in Alzheimer’s disease (Ianni et al., 2010). The changes in patterns of 
glycosylation of transferrin (Tf) towards highly branched glycans have been observed in 
iron deficiency anaemia, rheumatoid arthritis, liver cirrhosis or in physiological state such as 
pregnancy. Differences in glycosylation of Tf seems to alter the metabolism of iron (Yang et 
al., 2005; van Pelt J et al., 1996; Dupre et al., 2001). Changes in the glycosylation pattern of 
major serum APPs such as Hp, AGP, AAT, Tf and alpha-fetoprotein have been recently 
shown in patients with pancreatic cancer and chronic pancreatitis (Sarrats et al., 2010) 
4.2 Cleaved forms of AAPs 
The cleaved modifications of APPs may lead to a functional deficiency of the protein, but 
the cleaved forms of APPs may themselves express new biological activities.  For example, 
antithrombin which functions as an inhibitor of thrombin and other enzymes, has potent 
antiangiogenic and antitumour activity in its cleaved conformation.  
4.2.1 CRP 
CRP comprises five identical, non-covalently bound subunits of 206 amino acids  (23,017 
daltons) arranged in cyclic symmetry (Oliveira et al., 1979). One side of the pentamer 
participates in binding ligands such as phosphorylcholine, and the other side binds effector 
molecules such as C1q. When CRP is exposed to denaturing conditions in the presence of a 
chelating agent, the CRP pentamer is altered to form both individual subunits and 
aggregates (Gotschlich & Edelman, 1967) designated as modified-CRP (mCRP) (Potempa et 
al., 1983). The half-life of mCRP in the circulation is <5 min in mice (Motie et al., 1998). These 
findings indicate that the transport of mCRP from circulation to various sites in the body 
most likely to be faster than pentameric CRP.  mCRP displays antigenic, electrophoretic, and 
ligand binding reactivities distinct from pentameric CRP (Potempa et al., 1987). Currently 
has been reported that mCRP is much more potent than pentameric CRP in binding to 
modified LDL (Singh & Fudenberg, 2009).   
Since extravasation and activation of neutrophil granulocytes are essential in the 
inflammatory response, the effects of CRP on these cells are of particular importance. 
Stimulation of neutrophils activates a membrane-associated serine protease which leads to 
the cleavage of biologically active peptides from CRP. CRP peptides 77–82 and 201–206 have 
been found to inhibit neutrophil chemotaxis to fMLP in vitro and to diminish neutrophil 
influx and protein leakage into alveoli after fMLP induced inflammation in mice (Zouki et 
al., 1997).  
Neutrophil extravasation into inflamed or injured areas involves a complex interaction of 
leukocytes with endothelial cells via regulated expression of surface adhesion molecules. 
The initial attachment of neutrophils to endothelium is mediated by L-selectin (CD62L) 
(Díaz-González et al., 1995; Walcheck et al., 1996). L-Selectin is constitutively expressed by 
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neutrophils and is released from neutrophils by proteolytic cleavage within minutes after 
activation with a concomitant upregulation of Mac-1 (CD11b/CD18). The monomeric CRP 
(but not nCRP) has been found to up-regulate CD11b/CD18 expression and extracellular 
signal regulated kinase (ERK) activity, suggesting that mCRP may participate in the 
promotion of neutrophil adhesion to endothelial cells (Zouki et al., 2001). In contrast to CRP, 
mCRP induces IL-8 secretion in neutrophils (Khreiss et al, 2005) and human coronary artery 
endothelial cells (Devaraj S et al., 2004), promotes neutrophil-endothelial cell adhesion 
(Zouki  et al., 2001), and delays apoptosis of human neutrophils (Schwedler  et al., 2006). 
mCRP binds to a number of different ligands to CRP and also exhibits a different set of 
biologic activities. More recently, it has been shown that mCRP has profound inhibitory 
effects on tumor growth and metastatic ability of an adenocarcinoma in mice (Kresl  et al., 
1999). Cross-reactive epitopes of mCRP have also been detected in the fibrous elements of 
blood vessels and lymphatic organs suggesting that mCRP may be present in extracellular 
spaces (Samberg et al., 1988). Since mCRP can self-associate into a matrix-like structure 
(Motie et al., 1996), the naturally occurring antigen may be self-associated aggregates of 
mCRP, and thus represent a tissue-based as opposed to a blood based form of CRP. mCRP, 
but not CRP, binds immune complexes (Khreiss et al., 2004), potentiates the activities of 
activated leukocytes and platelets (Zouki et al., 2001) and stimulates megakaryocyte 
differentiation in mice (Potempa et al, 1996).  
Additionally, both CRP conformations interact differently with components of the 
complement cascade. M Mihlan et al., 2009, identified for the first time that mCRP, but not 
pCRP, has a complement-modulating effect. mCRP recruits the complement inhibitor Factor 
H to the surface of damaged cells or particles, and  enhances local complement inhibition 
both in the fluid phase and on the cellular surface. Thus, by recruiting C1q to the surface of 
damaged cells, mCRP triggers complement activation resulting in the formation of C3 
convertases and C3b surface deposition. However, by binding inhibitor Factor H and 
enhancing the inhibitory activity, further complement activation, amplification, cytokine 
release, C9 deposition and terminal membrane attack assembly are inhibited. Furthermore, 
the phagocytosis of apoptotic particles is increased. This shows how CRP can contribute to 
an anti-inflammatory scenario and explains how mCRP contributes to the safe removal of 
damaged apoptotic particles and necrotic cells which may be relevant for diseases such as 
atherosclerosis (Zipfel& Skerka, 2009). 
Using immunofluorescence microscopy (Eisenhardt et al., 2009) have shown the generation 
of mCRP from CRP on adherent activated platelets, together with the immunohistological 
colocalization of mCRP with the CD41 antigen in atherosclerotic plaques. These findings 
suggest that in atherosclerosis mCRP is generated from circulating CRP, and mCRP is then 
deposited at the atherosclerotic plaque, exerting strong proinflammatory effects (Agrawal  et 
al., 2010). 
Despite the growing interest in mCRP, it remains unclear how mCRP is generated and 
whether it contributes to inflammatory processes such as atherosclerosis. Thus, it appears 
that both CRP and altered forms of CRP, including mCRP, may each serve important 
distinct functions in the acute phase and the host defense response to trauma and infectious 
agents. Therefore, it is important to ascertain the extent of conversion and reversion of CRP 
to mCRP and possible intermediate forms to help define and understand the biological 
function(s) of the CRP molecule. 
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4.2.2 AAT 
AAT is another example of AAP which can be found in vivo in cleaved forms. Cleaved forms 
of AAT are know to occur when AAT forms an inhibitor complex with serine protease 
which subsequently dissociates or is degraded, or when it is cleaved by non-target 
proteases, usually at sites in its reactive loop, without the formation of stable inhibitor 
complexes. Such cleavage generates a 4 kDa carboxyl-terminal fragment of 36 residues, 
which remains non-covalently bound to the cleaved AAT. Human cathepsin L, collagenase 
and stromelysin, and bacterial proteinases from Staphylococcus aureus, Serratia marcescens 
metalloproteinase and Pseudomonas aeruginosa elastase (Rapala-Kozik et al., 1999) all fall into 
the latter class and exhibit efficient AAT degrading activity. Recent studies established AAT 
as a key substrate for gelatinase B (MMP-9) in vivo (Liu et al., 2000). It has long been 
hypothesized that neutrophil elastase-mediated tissue destruction in certain inflammatory 
diseases such as emphysema, is caused by an imbalance in the ratio of elastase to AAT 
(Weiss, 1989). The studies of Liu and collaborators provide in vivo evidence that this 
mechanism, mediated by the proteolytic inactivation of AAT by gelatinase B, underlies the 
pathology of the inflammatory skin disorder called bullous pemphigoid which is initiated 
by deposit formation at the basement membrane (Jordon et al., 1985). Generated cleaved 
forms of AAT may contribute to the later phase of polymorphonuclear leukocyte 
infiltration. Indeed, cleaved AAT was shown to form fibrillar structures and to be a potent 
chemoattractant for monocytes (Janciauskiene et al., 1995; Banda et al., 1988).  
Fragments of AAT have been found in human bile, atherosclerotic plaque, urine and 
plasma, and have been shown to regulate lipid metabolism, inflammatory cell activation 
and even to inhibit human HIV-1 expression. It has recently been demonstrated that a 
specific 20-residue fragment of AAT (C-terminal peptide, residues 377–396, referred to as 
VIRIP) binds to the gp41 fusion peptide of HIV-1 and prevents the virus from entering 
target cells, thereby inhibiting HIV-1 infection (Münch  et al, 2007). These findings suggest 
that AAT may play a protective role in HIV-1-infected individuals (Forssmann et al., 2010). 
We found that the C-terminal fragment of AAT, C-36 peptide, corresponding to residues 
359-394 suppresses bile acid synthesis in vitro and in vivo. The DNA element involved in the 
C-36-mediated regulation of 7alpha- and 12alpha-hydroxylase promoters mapped to the 
alpha1-fetoprotein transcription factor site in both promoters. The C-36 peptide prevented 
binding of FTF to its target DNA recognition site by direct interaction with FTF (Gerbod-
Giannone et al., 2002). Hence, the effects of AAT peptides as potential drugs for systemic 
lupus erythematosus are being studied (Shapira et al., 2011). 
4.3 Oxidized and nitrosylated forms of APPs 
Under conditions of compromised oxygen supply, such as occurs in injury, infection or 
malignancy, oxygen species with free unpaired electrons are generated during 
mitochondrial electron transport. Referred to as highly reactive oxygen species (ROS), their 
production causes damage to cell membranes and macromolecules (lipids, proteins and 
DNA) (Valko et al., 2007). Oxidative changes of protein structure can have a wide range of 
downstream functional consequences, such as inhibition of enzymatic and binding 
activities, increased susceptibility to aggregation and proteolysis, increased or decreased 
uptake by cells, and altered immunogenicity. It is now recognized that oxidation of proteins 
plays an essential role in the pathogenesis of an important number of degenerative diseases. 
Compared to controls more oxidized proteins are found in tissues from animals and patients 
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suffering from Alzheimer's disease, rheumatoid arthritis, atherosclerosis or amyotrophic 
lateral sclerosis (Banfi et al., 2008). For example, in plasma from patients with Alzheimer`s 
disease the most obviously oxidized proteins were identified as isoforms of AAT and 
fibrinogen Ǆ-chain precursor proteins. Both these proteins have been suggested to be 
involved in inflammation processes in Alzheimer's disease (Choi et al., 2002).  
S-nitrosylation is another important post-transcriptional modification of the APPs and their 
peptides, which may be involved in NO-dependent signal transductions. For example, a 
recent study indicates that S-nitrosylation can be effectively catalyzed by the copper ion of 
ceruloplasmin, a major multicopper-containing plasma protein, under physiological 
conditions (Mani et al., 2004). It is now also conceivable that nitrosylation of thiols is 
involved in modulation of various biological events, such as functional regulation of 
receptors, ion channels and synaptic vesicle fusion (Miyamoto et al., 2000). 
4.3.1 AAT 
Oxidized AAT has been found in inflammatory exudates at levels of ~5–10% that of total 
AAT (Wong &Travis, 1988), and AAT recovered from BAL fluid in smokers is 40% less 
active compared with non-smokers due to oxidation of the P1 methionine (methionine 358 
at the active site) to methionine sulfoxide (Carp et al., 1982). The oxidation of AAT by 
cigarette smoke or free radicals in vivo has been proposed as a mechanism by which elastin 
and thus alveolar destruction occurs in COPD (Gadek et al., 1979; Beatty et al., 1984). 
Oxidation of the P1 methionine (methionine 358) or methionine 351 to methionine sulfoxide 
significantly reduces the ability of AAT to inhibit neutrophil elastase (Taggart et al., 2000). 
Hydrogen peroxide in cigarette smoke and N-chloroamines and hypochlorous acid in 
neutrophils can oxidize and inactivate AAT (Ossanna et al., 1986; Scott et al., 1999). Thus the 
oxidation of AAT by cigarette smoke or free radicals in vivo could lead to a relative 
deficiency of elastase inhibitors and has been suggested as a mechanism contributing to the 
development of emphysema and other diseases such as cystic fibrosis, adult respiratory 
distress syndrome, and bronchiectasis (McGuire et al., 1982; Roum et al., 1993; Izumi-
Yoneda et al., 2009). In addition, oxidative inactivation can enhance the susceptibility of 
AAT to proteolytic attack, particularly by neutrophil elastase and certain bacterial proteases, 
including thermolysin, aureolysin, serralysin, pseudolysin, Staphylococcus aureus serine 
proteinase, streptopain and periodontain. Thus, oxidation and proteolytic processes in some 
cases may work synergistically. Moreover, oxidized AAT by itself amplifies and perpetuates 
the inflammatory processes by directly affecting the functional activities of structural and 
inflammatory cells or by interacting with other molecules such as IgA and low-density 
lipoproteins. It has been shown that oxidized AAT significantly induces the production of 
IL-8 and MCP-1 from a lung epithelial cell line (A549 cells) and in a time- and dose-
dependent manner and attracts macrophages (Li et al., 2009).  Release of oxidants by these 
inflammatory cells could oxidize newly synthesized AT, which has diffused into the airways 
and would perpetuate the cycle. This process may be amplified by oxidized AAT induction 
of MCP-1 synthesis from monocytes (Moraga & Janciauskiene, 2000). These pathways may 
be one explanation as to why inflammation persists after smoking cessation in chronic 
obstructive pulmonary disease (Retamales et al., 2001). A complex of oxidized AAT and 
LDL was isolated from human plasma and was detected in human atherosclerotic lesions of 
the coronary artery (Donners et al., 2005). The product of AAT nitrosylation, S-NO-AAT, has 
been shown to have multiple biological functions, including potent anti-microbial activity 
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and inhibition of cysteine protease. In a  study by Ikebe and co-workers (Ikebe et al., 2000) it 
was suggested that S-NO-AAT exerted a potent cytoprotective effect in liver ischemia-
reperfusion injury by maintaining the tissue blood flow, inducing hemeoxygenase 1, and 
suppressing neutrophil-induced liver damage and apoptosis. Interestingly, it was verified 
that S-NO-AAT expressed similar serine protease inhibitory activity towards pancreatic 
trypsin and pancreatic and neutrophil elastase as native AAT. Thus, S-NO-AAT may 
function not only as a simple NO (nitroso) donor but also as a protease inhibitor with a 
broad inhibitory spectrum.  
4.4 Complexed and polymerized forms of APPs 
Function of some APPs is dependent on their complex formation with other molecules 
and/or on their polymerization. For example, CRP binds to phosphocholine, as well as 
phosphoethanolamine, microbial surface proteins, chromatin and other ligands (Thompson 
et al., 1999; Agrawal et al., 2002, Okemefuna et al, 2010). CRP activates the classical pathway 
of complement by binding to C1q, but its binding to CFH in the alternative pathway has 
turned out to be more controversial. CRP–ligand interactions lead to the recognition of 
damaged or apoptotic cells and bacterial pathogens. Ca2+ and phosphocholine bind to the B 
(binding) face of the pentameric ring, whereas the other A (ǂ-helix) face binds to 
macromolecular ligands such as C1q. The complex  between Hp and Hemoglobin has been 
studied for decades and represents one of the strongest non-covalent interactions reported in 
plasma (Nielsen & Moestrup, 2009). Hp also binds apolipoprotein A-I (ApoA-I), and impairs 
its stimulation of lecithin: cholesterol acyltransferase (LCAT) which plays a major role in 
reverse cholesterol transport (Cigliano et al., 2009). Hp binds and protects ApoE from 
oxidative damage (Salvatore et al., 2009). Some APPs are regulated by co-factors which are 
needed to expose or maintain the functional conformation of the APP.  The best example of 
this phenomenon is antithrombin, which is activated by heparin through induced and 
transmitted conformational changes that stabilise the proteinase-sensitive active site (Jodan 
et al., 1987). Another APP, PAI-1, which normally exists in a latent form, can be maintained 
in its functional form in the presence of plasma vitronectin (Wiman et al., 1988). As well as 
stabilising PAI-1 in the active conformation, vitronectin also alters the specificity of PAI-1, 
making it an efficient inhibitor of thrombin. The finding that active PAI-1 specifically 
inhibits integrin attachment to vitronectin (Stefansson & Lawrence, 1996) further illustrates 
the unique functional interdependence that exists between PAI-1 and vitronectin. 
Complexes between APPs and other proteins are also found to be associated with specific 
diseases. For example, in sera from patients with myeloma and Bence-Jones proteinuria, 
complexes between AAT and the kappa light chain of immunoglobulins were detected 
(Laurell et al., 1974). In plasma from diabetic subjects, complexes between AAT and factor 
Xia, and AAT and heat shock protein-70 (HSP70), as well as glycosylated forms of AAT 
were detected (Austin et al., 1987; Scott et al., 1998; Finotti et al., 2004). Moreover, complexes 
between immunoglobulin A and AAT have been detected in the sera and synovial fluid of 
patients with rheumatoid arthritis, systemic lupus erythematosus and ankylosing 
spondylitis (Scott et al., 1998). Human tissue kallikrein 3, a serine proteinase commonly 
known as a prostate-specific antigen (PSA) which correlates with prostate hypertrophy and 
malignancy, is also known to bind to AAT in sera of subjects with high PSA concentrations 
(Zhang et al., 2000). Localization of AAT-low-density-lipoprotein (LDL) complexes in 
atherosclerotic lesions and enhanced degradation of AAT-LDL by macrophages suggested 
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the involvement of the complex in atherogenesis (Donners et al., 2005). Alpha1-
antichymotrypsin/Alzheimer's peptide Abeta (1-42) complexes and ACT polymers have 
been associated with Alzheimer's disease (Licastro et al., 1997;  Sun et al., 2002).Studies of 
the functional and conformational polymorphism of inhibitory APPs clearly show that some 
proteins can undergo polymerization due to an inherited mutation, or chemical 
modification, and obtain new biological activities or reflect undergoing pathological 
process. A well-characterised example of a mutant APP associated with a disease state is 
AAT. The most widely studied deficiency variants of AAT are Z and S, which have E342K 
and E264V mutations respectively (Carrell et al., 1996; Carrell et al., 1892). Polymerisation of 
these mutants of AAT is known to be involved in AAT deficiency-related diseases such as 
emphysema, liver cirrhosis, neonatal hepatitis, hepatocellular carcinoma and lung 
emphysema (Eriksson, 1990) The liver pathology is characterised by the formation of 
intracellular inclusions of polymerised AAT. Recent studies now indicate that extra-hepatic 
AAT polymerization may also occur. For example, AAT polymers have been identified in 
the lungs and circulation of Z AAT deficiency subjects. Importantly, like other modified 
forms, AAT polymers lack protease inhibitor activity which will exaggerate the severe 
deficiency, but also exhibit additional biological functions that may be relevant in 
pathological processes (Mahadeva et al., 2005; Mulgrew et al., 2004) (Figure 5). The 
susceptibility of Z AAT individuals who smoke to develop chronic obstructive pulmonary 
disease is in part related to the combination of the severe anti-elastase deficiency arising 
from an absolute and functional reduction in neutrophil elastase inhibitory capacity (Stoller 
& Aboussouan, 2005), and the independent multiple effects of cigarette smoke on 
inflammatory cells and molecules (Barnes et al., 2003). Our current data clearly demonstrate 
that cigarette smoke promotes polymerization of Z mutant AAT, but not of the normal, M 
variant of AAT. Thus cigarette smoke directly accelerates polymerization of Z AAT via 
oxidation of the protein leading to further depletion of the neutrophil protease protection in 
the lung and enhanced neutrophil influx (Alam et al., 2010). The data uniquely suggests that 
rather than the major risk factors for chronic obstructive pulmonary disease namely 
cigarette smoke and Z AAT deficiency having independent additive effects, they directly 
interact to create an effect greater than the sum of the individual risks.  
5. General conclusions 
Inflammation is a complex, highly orchestrated process involving many cell types and 
molecules, some of which initiate, amplify, or sustain the process, some of which attenuate it, 
and some of which aid resolution. A number of the participating AAPs are multifunctional 
and contribute to both the enhancement and the inhibition of inflammation at different points 
in its evolution. The outcome of the acute inflammatory response is most likely to be 
determined by the orchestrated generation of a specific profile of APPs, their concentrations 
and molecular forms in the microenvironment. Diseases associated with chronic inflammation 
may be due to an inadequate acute-phase response driven by APPs, their concentration and 
molecular form and/or an inability to eliminate invading pathogens and to rapidly to resolve 
the inflammatory processes. Often, a single APP is regarded as a marker for inflammation to 
aid in diagnosis and assesses response to treatement, however we believe one needs to see the 
profile of several APPs in action to understand function in relation to disease which may help 
in turn to determine prognosis.  
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Fig. 4. Schematic diagram showing proposed model for the pathogenesis of emphysema in 
patients with inherited Z AAT deficiency. Cigarette smoke induces significant oxidation of 
Z AAT, which accelerates AAT protein polymerization. The plasma deficiency and reduced 
inhibitory activity of Z AAT would be exacerbated by the oxidation and polymerization of 
AAT within the lungs, thereby further reducing the antiproteinase screen. This together 
with the loss of the normal inhibitory effect of AAT on neutrophil chemotaxis and the 
chemoattractant ability of ΑAT polymers thereby increase tissue damage and  accelerate 
emphysema progression. 
6. Acknowledgment 
RM is supported by the Cambridge NIHR Biomedical Research centre. SJ is supported by 
Hannover Medical School, Germany. 
7. References 
Agrawal, A, Elhanan, G & Halper, M. (2010). Dissimilarities in the Logical Modeling of 
Apparently Similar Concepts in SNOMED CT. AMIA Annu Symp Proc 2010, 212-216. 
www.intechopen.com
 
Acute Phase Proteins – Regulation and Functions of Acute Phase Proteins 
 
48
Alam, S, Li Z, Janciauskiene, S, & Mahadeva, R. (2010). Oxidation of Z {alpha}1-antitrypsin 
by Cigarette Smoke Induces Polymerization: A Novel Mechanism of Early-onset 
Emphysema. Am J Respir Cell Mol Biol Epub ahead of print. 
Al-Omari, M, et al. (2011). The acute phase protein, alpha1-antitrypsin, inhibits neutrophil 
calpain I and induces random migration. Mol Med Apr 11 [Epub ahead of print]. 
Anderson, N, et al. (2002). A preliminary evaluation of the differences in the glycosylation of 
alpha-1-acid glycoprotein between individual liver diseases. Biomed Chromatogr 16, 
365-372. 
Arredouani, M, et al. (2003). Haptoglobin directly affects T cells and suppresses T helper cell 
type 2 cytokine release. Immunology 108, 144-151. 
Assicot, M, et al. (1993). High serum procalcitonin concentrations in patients with sepsis and 
infection. Lancet 341, 515-518. 
Austin, GE, Mullins, RH & Morin, LG. (1987). Non-enzymic glycation of individual plasma 
proteins in normoglycemic and hyperglycemic patients. Clin Chem 33, 2220-2224. 
Ballou, SP& Lozanski G. (1992). Induction of inflammatory cytokine release from cultured 
human monocytes by C-reactive protein. Cytokine 4, 361-368 
Banda, MJ, Rice, AG, Griffin, GL, & Senior, RM. (1988). Alpha 1-proteinase inhibitor is a 
neutrophil chemoattractant after proteolytic inactivation by macrophage elastase. J 
Biol Chem 263, 4481-4484. 
Banfi, C, et al. (2008). Oxidized proteins in plasma of patients with heart failure: role in 
endothelial damage. Eur J Heart Fail 10, 244-251. 
Barnes, PJ. (2003). New treatments for chronic obstructive pulmonary disease. Ann Ist Super 
Sanita 39, 573-582. 
Barter ,PJ, et al. (2004). Antiinflammatory properties of HDL. Circ Res 95, 764-772. 
Beatty, K, Matheson, N, & Travis, J. (1984). Kinetic and chemical evidence for the inability of 
oxidized alpha 1-proteinase inhibitor to protect lung elastin from elastolytic 
degradation. Hoppe Seylers Z Physiol Chem 365, 731-736. 
Berg, RD. (1996). The indigenous gastrointestinal microflora.Trends Microbiol 4, 430-435. 
Bergin, DA, et al. (2010). ǂ-1 Antitrypsin regulates human neutrophil chemotaxis induced by 
soluble immune complexes and IL-8. J Clin Invest 120, 4236-4250. 
Berman, S, Gewurz, H, & Mold, C. (1986). Binding of C-reactive protein to nucleated cells 
leads to complement activation without cytolysis. J Immunol 136, 1354-1359. 
Bisoendial, R, et al. (2005). In vivo effects of C-reactive protein (CRP)-infusion into humans. 
Circ Res 97, e115-116. 
Blackburn, WD. (1994). Validity of acute phase proteins as markers of disease activity. J 
Rheumatol 42, 9–13. 
Blanco, I, et al. (2006). Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-
antitrypsin deficiency in European countries. Eur Respir J 27, 77-84. 
Boutten, A, et al. (1992). Alpha 1-acid glycoprotein potentiates lipopolysaccharide-induced 
secretion of interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha by 
human monocytes and alveolar and peritoneal macrophages. Eur J Immunol 22, 
2687-2695. 
Brand, K, et al. (1996). Activated transcription factor nuclear factor-kappa B is present in the 
atherosclerotic lesion. J Clin Invest 97, 1715-1722. 
Brinckerhoff, CE, et al. (1989). Autocrine induction of collagenase by serum amyloid A-like 
and beta 2-microglobulin-like proteins. Science 243, 655-7. 
Bucurenci, N, et al. (1992). Inhibition of neutrophil superoxide production by human plasma 
alpha 1-antitrypsin. FEBS Lett 300, 21-24. 
www.intechopen.com
 
Acute Phase Proteins: Structure and Function Relationship 
 
49 
Carp, H, et al. (1982). Potential mechanism of emphysema: alpha 1-proteinase inhibitor 
recovered from lungs of cigarette smokers contains oxidized methionine and has 
decreased elastase inhibitory capacity. Proc Natl Acad Sci U S A 79, 2041-2045. 
Carrell , R. (1986). alpha 1-Antitrypsin: molecular pathology, leukocytes, and tissue damage. 
J Clin Invest 78, 1427-1431. 
Carrell, RW, & Lomas, DA. (1997). Conformational disease. Lancet 350, 134-138. 
Carrell, RW, et al. (1996). Alpha 1-antitrypsin deficiency. A conformational disease. Chest 
110, 243S-247S. 
Casey, R, et al. (2008). The acute-phase reactant C-reactive protein binds to 
phosphorylcholine-expressing Neisseria meningitidis and increases uptake by 
human phagocytes. Infect Immun 76, 1298-1304. 
Cermak, J, et al. (1993). Cell heme uptake induces ferritin synthesis resulting in altered 
oxidant sensitivity: possible role in chemotherapy efficacy. Tumor Cancer Res 53, 
5308-5313. 
Chapman, KR, Stockley, RA, Dawkins, C, Wilkes, MM, & Navickis, RJ. (2009). 
Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD 6, 
177-184. 
Cheng, N, et al. (2008). Cutting edge: TLR2 is a functional receptor for acute-phase serum 
amyloid A. J Immunol. 181, 22-26. 
Choi, J, et al. (2002). Identification of oxidized plasma proteins in Alzheimer's disease. 
Biochem Biophys Res Commun 293, 1566-1570. 
Chowdhury, MM, et al. (2002). Severe panniculitis caused by homozygous ZZ alpha1-
antitrypsin deficiency treated successfully with human purified enzyme (Prolastin). 
Br J Dermatol 147, 1258-1261. 
Churg, A, et al. (2001). Alpha-1-antitrypsin and a broad spectrum metalloprotease inhibitor, 
RS113456, have similar acute anti-inflammatory effects. Lab Inves 81, 1119-1131. 
Cid, MC, et al. (1993). Identification of haptoglobin as an angiogenic factor in sera from 
patients with systemic vasculitis. J Clin Invest 91, 977-985. 
Cigliano, L, et al. (2009). Haptoglobin binds the antiatherogenic protein apolipoprotein E-
impairment of apolipoprotein E stimulation of both lecithin:cholesterol 
acyltransferase activity and cholesterol uptake by hepatocytes. FEBS J 276, 6158-
6171. 
Connolly, M, et al. (2010). Acute serum amyloid A induces migration, angiogenesis, and 
inflammation in synovial cells in vitro and in a human rheumatoid arthritis/SCID 
mouse chimera model. J Immunol 184, 6427-6437. 
Costello M, Fiedel BA & Gewurz H. (1979). Inhibition of platelet aggregation by native and 
desialised alpha-1 acid glycoprotein. Nature 281, 677-678. 
Costello, MJ, Gewurz, H & Siegel, JN. (1984). Inhibition of neutrophil activation by alpha1-
acid glycoprotein. Clin Exp Immunol 55, 465-472. 
Culley, FJ, et al. (1996). C-reactive protein binds to a novel ligand on Leishmania donovani 
and increases uptake into human macrophages. J Immunol 156, 4691-4696. 
Daemen, MA, et al. (2000). Functional protection by acute phase proteins alpha(1)-acid 
glycoprotein and alpha(1)-antitrypsin against ischemia/reperfusion injury by 
preventing apoptosis and inflammation. Circulation 102, 1420-1426. 
De Graaf, TW, et al. (1993). Inflammation-induced expression of sialyl Lewis X-containing 
glycan structures on alpha 1-acid glycoprotein (orosomucoid) in human sera. J Exp 
Med 177, 657-666. 
www.intechopen.com
 
Acute Phase Proteins – Regulation and Functions of Acute Phase Proteins 
 
50
Dehghan, A, et al. (2007). Risk of type 2 diabetes attributable to C-reactive protein and other 
risk factors. Diabetes Care 30, 2695-2699. 
De Martin, R, et al. (2000). The transcription factor NF-kappa B and the regulation of 
vascular cell function. Arterioscler Thromb Vasc Biol 20, E83-88. 
Devaraj, S, Kumaresan, PR & Jialal, I. (2004). Effect of C-reactive protein on chemokine 
expression in human aortic endothelial cells. J Mol Cell Cardiol 36, 405-410. 
De Santo, C, et al. (2010). Invariant NKT cells modulate the suppressive activity of IL-10-
secreting neutrophils differentiated with serum amyloid A. Nat Immunol 11, 1039-
1046. 
Díaz-González, F, et al. (1995). Prevention of in vitro neutrophil-endothelial attachment 
through shedding of L-selectin by nonsteroidal antiinflammatory drugs. J Clin 
Invest 95, 1756-1765. 
Dinarello, CA. (1983). Pathogenesis of fever during hemodialysis. Contrib Nephrol 36, 90–99. 
Donners, MM, et al. (2005). Proteomic analysis of differential protein expression in human 
atherosclerotic plaque progression. J Pathol 206, 39-45. 
Dowd, SK, Rodgers, GC, & Callen, JP. (1995). Effective treatment with alpha 1-protease 
inhibitor of chronic cutaneous vasculitis associated with alpha 1-antitrypsin 
deficiency. J Am Acad Dermatol 33, 913-916. 
Drenth JP, van der Meer JW & Kushner I. (1996). Unstimulated peripheral blood 
mononuclear cells from patients with the hyper-IgD syndrome produce cytokines 
capable of potent induction of C-reactive protein and serum amyloid A in Hep3B 
cells. J Immunol 157, 400-404. 
Du Clos, TW. (1989). C-reactive protein reacts with the U1 small nuclear ribonucleoprotein. J 
Immunol 143, 2553-2559. 
Du Clos, TW. (2000).  Function of C-reactive protein. Ann Med 32, 274-278. 
Du Clos, TW, Zlock, LT, & Rubin, RL. (1988). Analysis of the binding of C-reactive protein to 
histones and chromatin. J Immunol 141, 4266-4270. 
Dupre, T, et al. (2001). Congenital disorder of glycosylation Ia with deficient 
phosphomannomutase activity but normal plasma glycoprotein pattern. Clin Chem 
47, 132-134. 
Eaton, JW, et al. (1982). Haptoglobin: a natural bacteriostat. Science 215, 691-693. 
Eckhardt ER, et al. (2010). Intestinal epithelial serum amyloid A modulates bacterial growth 
in vitro and pro inflammatory responses in mouse experimental colitis. BMC 
Gastroenterol 10, 133. 
Edwards, DH, et al. (1986). Haptoglobin-haemoglobin complex in human plasma inhibits 
endothelium dependent relaxation: evidence that endothelium derived relaxing 
factor acts as a local autocoid. Cardiovasc Res 20, 549-556. 
Eisenhardt, SU, Habersberger, J & Peter, K. (2009). Monomeric C-reactive protein generation 
on activated platelets: the missing link between inflammation and 
atherothrombotic risk. Trends Cardiovasc Med 19, 232-237. 
Elliott, MA, et al. (1997). Investigation into the concanavalin A reactivity, fucosylation and 
oligosaccharide microheterogeneity of alpha 1-acid glycoprotein expressed in the 
sera of patients with rheumatoidarthritis. J Chromatogr B Biomed Sci Appl 688, 229-
237. 
Engström, G, et al. (2004). Incidence of fatal or repaired abdominal aortic aneurysm in 
relation to inflammation-sensitive plasma proteins. Arterioscler Thromb Vasc Biol 24, 
337-341 
www.intechopen.com
 
Acute Phase Proteins: Structure and Function Relationship 
 
51 
Eriksen, N, & Benditt, EP. (1980). Isolation and characterization of the amyloid-related 
apoprotein (SAA) from human high density lipoprotein. Proc Natl Acad Sci U S A 
77, 6860-6864. 
Finotti, P, & Pagetta, A. (2004). A heat shock protein70 fusion protein with alpha1-
antitrypsin in plasma of type 1 diabetic subjects. Biochem Biophys Res Commun 315, 
297-305. 
Fournier, T, Medjoubi-N, N & Porquet, D. (2000). Alpha-1-acid glycoprotein. Biochim Biophys 
Acta 1482, 157-171. 
Forney, JR, Yang, S, & Healey, MC. (1996). Interaction of the human serine protease inhibitor 
alpha-1-antitrypsin with Cryptosporidium parvum. J Parasitol 82, 496-502. 
Fröhlander, N, Ljunggren, O, & Lerner, UH. (1991). Haptoglobin synergistically potentiates 
bradykinin and thrombin induced prostaglandin biosynthesis in isolated 
osteoblasts. Biochem Biophys Res Commun 178, 343-351. 
Gabay, C, & Kushner, I. (1999). Acute-phase proteins and other systemic responses to 
inflammation. N Engl J Med 340: 448-454. 
Gadek, JE, Fells, GA, & Crystal, RG. (1979). Cigarette smoking induces functional 
antiprotease deficiency in the lower respiratory tract of humans. Science 206, 1315-
1316. 
Gerbod-Giannone, MC, et al. (2002). Suppression of cholesterol 7alpha-hydroxylase 
transcription and bile acid synthesis by an alpha1-antitrypsin peptide via 
interaction with alpha1-fetoprotein transcription factor. J Biol Chem 277, 42973-
42980. 
Gershov, D, et al. (2000). C-Reactive protein binds to apoptotic cells, protects the cells from 
assembly of the terminal complement components, and sustains an 
antiinflammatory innate immune response: implications for systemic 
autoimmunity. J Exp Med 192, 1353-1364. 
Gettins, PG. (2002). Serpin structure, mechanism, and function. Chem Rev 102, 4751-4804. 
Graziadei, I, et al. (1997). Unidirectional upregulation of the synthesis of the major iron 
proteins, transferrin-receptor and ferritin, in HepG2 cells by the acute-phase 
protein alpha1-antitrypsin. J Hepatol 27, 716-725. 
Gitlin, JD, Gitlin, JI, & Gitlin, D. (1977). Localizing of C-reactive protein in synovium of 
patients with rheumatoid arthritis. Arthritis Rheum 20, 1491-1499. 
Griese, M, et al. (2007). alpha1-Antitrypsin inhalation reduces airway inflammation in cystic 
fibrosis patients. J Eur Respir 29, 240-250. 
Gooptu, B, & Lomas, DA. (2009). Conformational pathology of the serpins: themes, 
variations, and therapeutic strategies. Annu Rev Biochem 78, 147-176. 
Gross, B, et al. (2009). New Findings in PiZZ alpha1-antitrypsin deficiency-related 
panniculitis.Demonstration of skin polymers and high dosing requirements of 
intravenous augmentation therapy. Dermatology 218, 370-375. 
Gruys, E, Obwolo, MJ, & Toussaint, MJ. (1994) Diagnostic significance of the major acute 
phase proteins in veterinary clinical chemistry: a review. Vet Bull 64, 1009–1018. 
Gotschlich, EC & Edelman, GM. (1967). Binding properties and specificity of C-reactive 
protein. Proc Natl Acad Sci U S A 57, 706-712. 
Gutsmann, T, et al. (2001). Dual role of lipopolysaccharide (LPS)-binding protein in 
neutralization of LPS and enhancement of LPS-induced activation of mononuclear 
cells. Infect Immun 69, 6942-6950. 
Hack, CE, et al. (1997). Role for secretory phospholipase A2 and C-reactive protein in the 
removal of injured cells. Immunol Today 18, 111-115. 
www.intechopen.com
 
Acute Phase Proteins – Regulation and Functions of Acute Phase Proteins 
 
52
Hanriot, D, et al. (2008). C-reactive protein induces pro- and anti-inflammatory effects, 
including activation of the liver X receptor alpha, on human monocytes. Thromb 
Haemost. 99, 558-569. 
Hattori, Y, Matsumura, M, Kasai, K. (2003). Vascular smooth muscle cell activation by C-
reactive protein. Cardiovasc Res 58, 186-195. 
Havenaar, EC, et al. (1998). Severe rheumatoid arthritis prohibits the pregnancy-induced 
decrease in alpha3-fucosylation of alpha1-acid glycoprotein. Glycoconj J 15, 723-729. 
Haverkate, F, et al. (1997). Production of C-reactive protein and risk of coronary events in 
stable and unstable angina. European Concerted Action on Thrombosis and 
Disabilities Angina Pectoris Study Group. Lancet 349, 462-466. 
He, R, Sang, H & Ye, RD. (2003). Serum amyloid A induces IL-8 secretion through a G 
protein-coupled receptor, FPRL1/LXA4R. Blood 101, 1572-1581. 
Heuertz, RM, et al. (1999). C-reactive protein inhibits chemotactic peptide-induced p38 
mitogen-activated protein kinase activity and human neutrophil movement. J Biol 
Chem 274, 17968-17974. 
Hochepied, T, et al. (2003). Alpha(1)-acid glycoprotein: an acute phase protein with 
inflammatory and immunomodulating properties. Cytokine Growth Factor Rev 14, 
25-34. 
Hrycaj, P, et al. (1996). Microheterogeneity of acute-phase glycoproteins in patients with 
pulmonary sarcoidosis. Eur Respir J  9, 313-318 
Ianni, M, et al. (2010). Altered glycosylation profile of purified plasma ACT from 
Alzheimer's disease. Immun Ageing 7 Suppl, S6. 
Ikebe, N, et al. (2000). Protective effect of S-nitrosylated alpha(1)-protease inhibitor on 
hepatic ischemia-reperfusion injury. J Pharmacol Exp Ther 295, 904-911. 
Ingenbleek, Y, & Bernstein L. (1999). The stressful condition as a nutritionally dependent 
adaptive dichotomy. Nutrition 15, 305–320. 
Izumi-Yoneda, N, et al. (2009). Alpha-1 antitrypsin activity is decreased in human amnion in 
premature rupture of the fetal membranes. Mol Hum Reprod 15, 49-57. 
Jahangiri, A, et al. (2009). HDL remodeling during the acute phase response. Arterioscler 
Thromb Vasc Biol 29, 261-267. 
Janciauskiene, S. (2001). Conformational properties of serine proteinase inhibitors (serpins) 
confer multiple pathophysiological roles. Biochim Biophys Acta 1535, 221-235. 
Janciauskiene, S, Carlemalm, E, & Eriksson, S. (1995). In vitro fibril formation from alpha1-
antitrypsin-derived C-terminal peptides. Biol Chem Hoppe Seyler 376, 415-423. 
Janciauskiene, SM, Nita, IM, & Stevens, T. (2007). Alpha1-antitrypsin, old dog, new tricks. 
Alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes 
by elevating cAMP. J Biol Chem 282, 8573-8582. 
Janciauskiene, S, et al. (2008). Alpha1-antitrypsin inhibits the activity of the matriptase 
catalytic domain in vitro. Am J Respir Cell Mol Biol 39, 631-637. 
Janciauskiene, SM, et al. (2011). The discovery of ǂ1-antitrypsin and its role in health and 
disease. Respir Med. [Epub ahead of print]. 
Javid, J. (1978). Human haptoglobins. Curr Top Hematol 1, 151-192. 
Jie, Z, et al. (2003). Protective effects of alpha 1-antitrypsin on acute lung injury in rabbits 
induced by endotoxin. Chin Med J (Engl) 116, 1678-1682. 
Jones, SA, et al. (1999). C-reactive protein: a physiological activator of interleukin 6 receptor 
shedding. J Exp Med 189, 599-604. 
Jordon, RE, Kawana, S, & Fritz, KA. (1985). Immunopathologic mechanisms in pemphigus 
and bullous pemphigoid. J Invest Dermatol 85, 72s-78s. 
www.intechopen.com
 
Acute Phase Proteins: Structure and Function Relationship 
 
53 
Kalis, M, et al. (2010). ǂ 1-antitrypsin enhances insulin secretion and prevents cytokine-
mediated apoptosis in pancreatic ǃ-cells. Islets 2, 185-189. 
Kakehi, K, Kinoshita, M & Nakano, M. (2002). Analysis of glycoproteins and the 
oligosaccharides thereof by high-performance capillary electrophoresis-significance 
in regulatory studies on biopharmaceutical products. Biomed Chromatogr 16, 103-
115. 
Kaźmierczak, M, et al. (1995). Changes of acute phase proteins glycosylation profile as a 
possible prognostic marker in myocardial infarction. Int J Cardiol 49, 201-207. 
Kew, RR, Hyers, TM, & Webster, RO. (1990). Human C-reactive protein inhibits neutrophil 
chemotaxis in vitro: possible implications for the adult respiratory distress 
syndrome. J Lab Clin Med 115, 339-345. 
Khreiss, T, et al. (2004). Opposing effects of C-reactive protein isoforms on shear-induced 
neutrophil-platelet adhesion and neutrophil aggregation in whole blood. 
Circulation 110, 2713-2720. 
Khreiss, T, et al. (2005). Loss of pentameric symmetry inC-reactive protein induces 
interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Circ 
Res 97, 690-697. 
Knappstein, S, et al. (2004). Alpha 1-antitrypsin binds to and interferes with functionality of 
EspB from atypical and typical enteropathogenic Escherichia coli strains. Infect 
Immun 72, 4344-4350. 
Koenig, W, et al. (1999). C-Reactive protein, a sensitive marker of inflammation, predicts 
future risk of coronary heart disease in initially healthy middle-aged men: results 
from the MONICA (Monitoring Trends and Determinants in Cardiovascular 
Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99, 237-242. 
Koenig, W, et al. (2006). Increased concentrations of C-reactive protein and IL-6 but not IL-
18 are independently associated with incident coronary events in middle-aged men 
and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-
2002. Arterioscler Thromb Vasc Biol 26, 2745-2751. 
Koulmanda, M, et al. (2008). Curative and beta cell regenerative effects of alpha1-antitrypsin 
treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci U S A 105, 16242-
16247. 
Koj , A. (1985) Cytokines regulating acute inflammation and synthesis of acute phase 
proteins. Blut 51, 267-274. 
Kresl, JJ, Potempa, LA, Anderson, B & Radosevich, JA.(1999). Inhibition of mouse mammary 
adenocarcinoma (EMT6) growth and metastases in mice by a modified form of C-
reactive protein. Tumour Biol 20, 72-87. 
Kueppers, F. (2011). The role of augmentation therapy in alpha-1 antitrypsin deficiency. 
Curr Med Res Opin 27, 579-588. 
Kurosky, A, et al. (1980). Covalent structure of human haptoglobin: a serine protease 
homolog. Proc Natl Acad Sci U S A 77, 3388-3392. 
Kushner, I. (1982). The phenomenon of the acute phase response. Ann N Y Acad Sci 389, 39-
48. 
Kushner, I & Feldmann, G. (1978). Control of the acute phase response. Demonstration of C-
reactive protein synthesis and secretion by hepatocytes during acute inflammation 
in the rabbit. J Exp Med 148, 466-77. 
Kushner, I, Gewurz, H, & Benson, MD. (1981). C-reactive protein and the acute-phase 
response. J Lab Clin Med 97, 739-749. 
www.intechopen.com
 
Acute Phase Proteins – Regulation and Functions of Acute Phase Proteins 
 
54
Kushner, I, & Mackiewicz, A. (1993). The acute-phase response: an overview. In: Acute Phase 
Proteins Molecular Biology, Biochemistry and Clinical Applications pp: 3-19. CRC  Press, 
Boca Raton, FL. 
Laine, A, et al. (1990). Comparison of the effects of purified human alpha 1-
antichymotrypsin and alpha 1-proteinase inhibitor on NK cytotoxicity: only alpha 
1-proteinase inhibitor inhibits natural killing. Clin Chim Acta 190, 163-173. 
Laurell, CB, & Thulin, E. (1974). Complexes in plasma between light chain kappa 
immunoglobulins and alpha 1-antitrypsin respectively prealbumin. 
Immunochemistry 11, 703-709. 
Lerner, UH, & Fröhlander, N. (1992). Haptoglobin-stimulated bone resorption in neonatal 
mouse calvarial bones in vitro. Arthritis Rheum 35, 587-591. 
Lewis, EC, et al. (2008). Alpha1-Antitrypsin monotherapy induces immune tolerance during 
islet allograft transplantation in mice. Proc Natl Acad Sci U S A 105, 16236-16241. 
Liang, YJ, et al. (2006). C-reactive protein activates the nuclear factor-kappaB pathway and 
induces vascular cell adhesion molecule-1 expression through CD32 in human 
umbilical vein endothelial cells and aortic endothelial cells. J Mol Cell Cardiol 40, 
412-420. 
Libby ,P. (2002). Inflammation in atherosclerosis. Nature 420, 868-874. 
Libert, C, Brouckaert, P & Fiers, W. (1994). Protection by alpha 1-acid glycoprotein against 
tumor necrosis factor-induced lethality. J Exp Med 180, 1571-1575. 
Libert, C, et al. (1996). alpha1-Antitrypsin inhibits the lethal response to TNF in mice. J 
Immunol 157, 5126-5129. 
Li, Z, et al. (2009). Oxidized{alpha}1-antitrypsin stimulates the release of monocyte 
chemotactic protein-1 from lung epithelial cells: potential role in emphysema. Am J 
Physiol Lung Cell Mol Physiol 297, L388-400. 
Licastro, F, et al. (1997). Monomeric and polymeric forms of alpha-1 antichymotrypsin in 
sera from patients with probable late onset Alzheimer's disease. Dement Geriatr 
Cogn Disord 8, 337-342. 
Lieberman J. (2000). Augmentation therapy reduces frequency of lung infections in 
antitrypsin deficiency: a new hypothesis with supporting data. Chest 118, 1480-
1485. 
Lind, P, et al. (2004). Risk of myocardial infarction and stroke in smokers is related to 
plasma levels of inflammation-sensitive proteins. Arterioscler Thromb Vasc Biol 24, 
577-582. 
Liu, HM, Takagaki, K & Schmid, K. (1988). In vitro nerve-growth-promoting activity of 
human plasma alpha 1-acid glycoprotein. J Neurosci Res 20, 64-72. 
Liu, Z, et al. (2000). The serpin alpha1-proteinase inhibitor is a critical substrate for 
gelatinase B/MMP-9 in vivo. Cell 102, 647-655. 
Liu, C, et al. (2005). Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects 
of commercial C-reactive protein on various human endothelial cell types in vitro: 
implications of contaminating presence of sodium azide in commercial preparation. 
Circ Res 97, 135-143.  
Lu X, LY, et al. (2009). Decay-Accelerating Factor Attenuates C-Reactive Protein-Potentiated 
Tissue Injury After Mesenteric Ischemia/Reperfusion. J Surg Res [Epub ahead of 
print]. 
Luo, LY, et al. (2006). Characterization of human kallikreins 6 and 10 in ascites fluid from 
ovarian cancer patients. Tumour Biol 27, 227-234. 
www.intechopen.com
 
Acute Phase Proteins: Structure and Function Relationship 
 
55 
Lysenko, E, et al. (2000). The position of phosphorylcholine on the lipopolysaccharide of 
Haemophilus influenzae affects binding and sensitivity to C-reactive protein-
mediated killing. Mol Microbiol 35, 234-245. 
Lögdberg, L & Wester, L. (2000). Immunocalins: a lipocalin subfamily that modulates 
immune and inflammatory responses. Biochim Biophys Acta 1482, 284-297. 
Mackiewicz, A, et al. (1987). Monokines regulate glycosylation of acute-phase proteins. J Exp 
Med 166, 253-258. 
Maes, OC, et al. (2006). Characterization of alpha1-antitrypsin as a heme oxygenase-1 
suppressor in Alzheimer plasma. Neurobiol Dis 24, 89-100. 
Mahadeva, R, et al., (2005) Polymers of Z alpha1-antitrypsin co-localize with neutrophils in 
emphysematous alveoli and are chemotactic in vivo. Am J Pathol 166, 377-386 
Malle, E, & De Beer, FC. (1996). Human serum amyloid A (SAA) protein: a prominent acute-
phase reactant for clinical practice. Eur J Clin Invest 26, 427-435. 
Mani, K, et al. (2004). Involvement of glycosylphosphatidylinositol-linked ceruloplasmin in 
the copper/zinc-nitric oxide-dependent degradation of glypican-1 heparan sulfate 
in rat C6 glioma cells. J Biol Chem 279, 12918-12923 
Marumo, T, et al. (1997). Platelet-derived growthfactor-stimulated superoxide anion 
production modulates activation of transcription factor NF-kappaB and expression 
of monocyte chemoattractant protein1 in human aortic smooth muscle cells. 
Circulation 96, 2361-2367. 
McGuire, WW, et al. (1982). Studies on the pathogenesis of the adult respiratory distress 
syndrome. J Clin Invest 69, 543-553. 
Mills, K, et al. (2001). Identification of alpha(1)-antitrypsin variants in plasma with the use of 
proteomic technology. Clin Chem 47, 2012-22. 
Miyamoto, Y, Akaike, T, & Maeda, H. (2000). S-nitrosylated human alpha(1)-protease 
inhibitor. Biochim Biophys Acta 1477, 90-97. 
Mold, C, Gewurz, H, & Du Clos, TW. (1999).  Regulation of complement activation by C-
reactive protein. Immunopharmacology 42, 23-30. 
Mold, C, Kingzette, M, & Gewurz, H. (1984). C-reactive protein inhibits pneumococcal 
activation of the alternative pathway by increasing the interaction between factor H 
and C3b. J Immunol 133, 882-885. 
Mold, C, et al. (1981). C-reactive protein is protective against Streptococcus pneumoniae 
infection in mice. J Exp Med 54, 1703-8. 
Mold, C, et al. (2002). C-reactive protein mediates protection from lipopolysaccharide 
through interactions with Fc gamma R. J Immunol Today 169, 7019-7025. 
Moore, DF, et al. (1997). Alpha-1-acid (AAG,orosomucoid) glycoprotein: interaction with 
bacterial lipopolysaccharide and protection from sepsis. Inflammation 21, 69-82. 
Moraga, F, & Janciauskiene S. (2000). Activation of primary human monocytes by the 
oxidized form of alpha1-antitrypsin. J Biol Chem 275, 7693-7700. 
Moshage, HJ, et al. (1987). Study of the molecular mechanism of decreased liver synthesis of 
albumin in inflammation. J Clin Invest 79, 1635-1641. 
Motie, M, Schaul, KW & Potempa, LA. (1998). Biodistribution and clearance of 125I-labeled 
C-reactive protein and 125I-labeled modified C-reactive protein in CD-1 mice. Drug 
Metab Dispos 26, 977-981. 
Muchitsch, EM, Auer, W & Pichler, L. (1998). Effects of alpha 1-acid glycoprotein in different 
rodent models of shock. Fundam Clin Pharmacol. 12, 173-181. 
Mulgrew, AT, et al., (2004) Z alpha1-antitrypsin polymers in the lung and acts as a 
neutrophil chemoattractant. Chest, 125, 1952-1957. 
www.intechopen.com
 
Acute Phase Proteins – Regulation and Functions of Acute Phase Proteins 
 
56
Nielsen, MJ, & Moestrup, SK. (2009). Receptor targeting of hemoglobin mediated by the 
haptoglobins: roles beyond heme scavenging. Blood 114, 764-771. 
Oh, SK, Pavlotsky, N, & Tauber, AI. (1990). Specific binding of haptoglobin to human 
neutrophils and its functional consequences. J Leukoc Biol 47, 142-148. 
Oliveira, EB, Gotschlich, C & Liu, TY. (1979). Primary structure of human C-reactive protein. 
J Biol Chem 254, 489-502. 
Okemefuna, AI, et al. (2010). C-reactive protein exists in an NaCl concentration-dependent 
pentamer-decamer equilibrium in physiological buffer. J Biol Chem 285, 1041-1052. 
Ossanna, PJ, et al. (1986). Oxidative regulation of neutrophil elastase-alpha-1-proteinase 
inhibitor interactions. J Clin Invest 77, 1939-1951. 
Pagano, M, Nicola, MA, & Engler, R. (1982). Inhibition of cathepsin L and B by haptoglobin, 
the haptoglobin-hemoglobin complex, and asialohaptoglobin. "In vitro" studies in 
the rat. Can J Biochem 60, 631-637. 
Pasceri, V, et al. (2001). Modulation of C-reactive protein-mediated monocyte 
chemoattractant protein-1 induction in human endothelial cells by anti-
atherosclerosis drugs. Circulation 103, 2531-2534. 
Pradhan, AD, et al. (2001). C-reactive protein, interleukin 6, and risk of developing type 2 
diabetes mellitus. JAMA 286, 327-334. 
Pasceri, V, Willerson, JT, & Yeh, ET. (2000). Direct proinflammatory effect of C-reactive 
protein on human endothelial cells. Circulation 102, 2165-2168. 
Pepys, MB, et al. (1994). Binding of pentraxins to different nuclear structures: C-reactive 
protein binds to small nuclear ribonucleoprotein particles, serum amyloid P 
component binds to chromatin and nucleoli. Clin Exp Immunol 97, 152-157. 
Petrache, I, et al. (2006). alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung 
endothelial cell apoptosis. Am J Pathol 169, 1155-1166. 
Pichler, L, Muchitsch,EM & Schwarz, HP. (1999). [Preclinical investigation of alpha 1-acid 
glycoprotein (orosomucoid)]. Wien Klin Wochenschr 111, 192-198. 
Poland, DC, et al. (2001). Increased alpha3-fucosylation of alpha1-acid glycoprotein in Type 
I diabetic patients is related to vascular function. Glycoconj J 18, 261-268. 
Potempa, LA, et al. (1983). Antigenic,electrophoretic and binding alterations of human C-
reactive protein modified selectively in the absence of calcium. Mol Immunol 20, 
1165-1175. 
Potempa, LA, et al. (1996). Stimulation of megakaryocytopoiesis in mice by human modified 
C-reactive protein (mCRP). Exp Hematol 24, 258-264. 
Potempa, LA, et al. (1987). Expression, detection and assay of a neoantigen (Neo-CRP) 
associated with a free, human C-reactive protein subunit. Mol Immunol 24, 531-541. 
Potthoff, AV, et al. (2007). HIV infection in a patient with alpha-1 antitrypsin deficiency: a 
detrimental combination? AIDS 21, 2115-2116. 
Rapala-Kozik, M, et al. (1999). Comparative cleavage sites within the reactive-site loop of 
native and oxidized alpha1-proteinase inhibitor by selected bacterial proteinases.  
Biol Chem 380, 1211-1216. 
Retamales, I, et al. (2001). Amplification of inflammation in emphysema and its association 
with latent adenoviral infection. Am J Respir Crit Care Med 164, 469-473. 
Ridker, PM, et al. (1997). Alu-repeat polymorphism in the gene coding for tissue-type 
plasminogen activator (t-PA) and risks of myocardial infarction among middle-
aged men. Arterioscler Thromb Vasc Biol 17, 1687-1690. 
www.intechopen.com
 
Acute Phase Proteins: Structure and Function Relationship 
 
57 
Rinaldi, M, et al. (2008). Differential effects of alpha1-acid glycoprotein on bovine neutrophil 
respiratory burst activity and IL-8 production. Vet Immunol Immunopathol 126, 199-
210. 
Rodriguez, W, et al. (2005). Reversal of ongoing proteinuria in autoimmune mice by 
treatment with C-reactive protein. Arthritis Rheum 52, 642-650. 
Rodriguez, W, et al. (2007). C-reactive protein-mediated suppression of nephrotoxic 
nephritis: role of macrophages, complement, and Fcgamma receptors. J Immunol 
178, 530-538. 
Rossbacher, J, Wagner, L, & Pasternack, MS. (1999). Inhibitory effect of haptoglobin on 
granulocyte chemotaxis, phagocytosis and bactericidal activity. Scand J Immunol 50, 
399-404. 
Roum, JH, et al. (1993). Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 75, 
2419-2424. 
Rydén, I, et al. (1997). Glycosylation of alpha1-acid glycoprotein in inflammatory disease: 
analysis by high-pH anion-exchange chromatography and concanavalin A crossed 
affinity immunoelectrophoresis. Glycoconj J 14, 481-488. 
Sadrzadeh, SM, & Bozorgmeh, J. (2004). Haptoglobin phenotypes in health and disorders. 
Am J Clin Pathol 121 Suppl. 
Salvatore A, et al. (2009). Haptoglobin binds apolipoprotein E and influences cholesterol 
esterification in the cerebrospinal fluid.J Neurochem. 110, 255-263. 
Saldova, R, et al. (2008). Glycosylation changes on serum glycoproteins in ovarian cancer 
may contribute to disease pathogenesis. Dis Markers 25, 219-232. 
Samberg, NL, et al. (1988). Preferential expression of neo-CRP epitopes on the surface of 
human peripheral blood lymphocytes. Cell Immunol 116, 86-98. 
Sarrats, A, et al. (2010). Glycosylation of liver acute-phase proteins in pancreatic cancer and 
chronic pancreatitis. Proteomics Clin Appl 4, 432-448. 
Scott, LJ, et al. (1998). Comparison of IgA-alpha1-antitrypsin levels in rheumatoid arthritis 
and seronegative oligoarthritis: complex formation is not associated with 
inflammation per se. Br J Rheumatol 37, 398-404. 
Sei, K, et al. (2002). Collection of alpha1-acid glycoprotein molecular species by capillary 
electrophoresis and the analysis of their molecular masses and carbohydrate chains. 
Basic studies on the analysis of glycoprotein glycoforms. J Chromatogr A 958, 273-
281. 
Shah, C, Hari-Dass, R & Raynes, JG. (2006). Serum amyloid A is an innate immune opsonin 
for Gram-negative bacteria. Blood 108, 1751-1757. 
Shapira, I, et al. (2011). Novel peptides as potential treatment of systemic lupus 
erythematosus. Lupus [Epub ahead of print]. 
Schapira, M, et al. (1982). Purified human plasma kallikrein aggregates human blood 
neutrophils. J Clin Invest 69, 1199-1202. 
She QB, et al. (2000). alpha(1)-antitrypsin can increase insulin-induced mitogenesis in 
various fibroblast and epithelial cell lines. FEBS Lett 473, 33-36. 
Schwedler, SB, et al. (2006). C-reactive protein: a family of proteins to regulate 
cardiovascular function. Am J Kidney Dis 47, 212-222. 
Singh, VK & Fudenberg, HH. (1986). Lymphocyte stimulation in vitro by orosomucoid 
glycoprotein. Immunol Lett 14, 9-13. 
Snyder, S & Coodley, EL. (1976). Inhibition of platelet aggregation by alpha1-acid 
glycoprotein. Arch Intern Med 136, 778-781. 
www.intechopen.com
 
Acute Phase Proteins – Regulation and Functions of Acute Phase Proteins 
 
58
Stefansson, S, & Lawrence, DA. (1996). The serpin PAI-1 inhibits cell migration by blocking 
integrin alpha V beta 3 binding to vitronectin. Nature 383, 441-443. 
Steinmetz, A, et al. (1989). Influence of serum amyloid A on cholesterol esterification in 
human plasma. Biochim Biophys Acta 1006, 173-178. 
Stibler, H, Holzbach, U & Kristiansson, B. (1998). Isoforms and levels of transferrin, 
antithrombin, alpha(1)-antitrypsin and thyroxine-binding globulin in 48 patients  
with carbohydrate-deficient glycoprotein syndrome type I. Scand J Clin Lab Invest 
58, 55-61. 
Stoller, JK, et al. (2007). Primary care diagnosis of alpha-1 antitrypsin deficiency: issues and 
opportunities. Cleve Clin J Med 74, 869-874. 
Stonik, JA, et al. (2004). Serum amyloid A promotes ABCA1-dependent and ABCA1-
independent lipid efflux from cells. Biochem Biophys Res Commun 32, 936-941. 
Su, SJ, et al. (1999). Alpha 1-acid glycoprotein-induced tumor necrosis factor-alpha secretion 
of human monocytes is enhanced by serum binding proteins and depends on 
protein tyrosine kinase activation. Immunopharmacology. 41, 21-29. 
Su, SJ & Yeh, TM. (1996). Effects of alpha 1-acid glycoprotein on tissue factor expression and 
tumor necrosis factor secretion in human monocytes. Immunopharmacology 34, 139-
145. 
Sun, YX, Wright, HT, & Janciauskiene, S. (2002). Alpha1-antichymotrypsin/Alzheimer's 
peptide Abeta(1-42) complex perturbs lipid metabolism and activates transcription 
factors PPARgamma and NFkappaB in human neuroblastoma (Kelly) cells. J 
Neurosci Respir Med 67, 511-522. 
Subramaniyam, D., et al. (2010). Cholesterol rich lipid raft microdomains are gateway for 
acute phase protein, SERPINA1. Int J Biochem Cell Biol 42, 1562-1570. 
Subramaniyam, D, et al. (2008). TNF-alpha-induced self expression in human lung 
endothelial cells is inhibited by native and oxidized alpha1-antitrypsin. Int J 
Biochem Cell Biol 40, 258-271. 
Subramaniyam, D., et al. (2010). Effects of alpha 1-antitrypsin on endotoxin-induced lung 
inflammation in vivo. Inflamm Res 59, 571-578. 
Sullivan, CP, et al. (2010). Secretory phospholipase A2, group IIA is a novel serum amyloid 
A target gene: activation of smooth muscle cell expression by an interleukin-1 
receptor-independent mechanism. J Biol Chem 285, 565-575. 
Szalai, AJ, Briles, DE & Volanakis, JE. (1995). Human C-reactive protein is protective against 
fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol 155, 2557-
2563. 
Szalai, AJ, et al. (2002). Experimental allergic encephalomyelitis is inhibited in transgenic 
mice expressing human C-reactive protein. J Immunol 168, 5792-5797. 
Szalai, AJ, et al. (2000). Human C-reactive protein is protective against fatal Salmonella 
enterica serovar typhimurium infection in transgenic mice. Infect Immun 68, 5652-
5656. 
Sörensson, J, et al. (1999). Human endothelial cells produce orosomucoid, an important 
component of the capillary barrier. Am J Physiol 276, H530-534. 
Tam, SP, Kisilevsky, R, & Ancsin, JB. (2008). Acute-phase-HDL remodeling by heparan 
sulfate generates a novel lipoprotein with exceptional cholesterol efflux activity 
from macrophages. PLoS One 3, e3867. 
Taggart, C, et al. (2000). Oxidation of either methionine 351 or methionine 358 in alpha 1-
antitrypsin causes loss of anti-neutrophil elastase activity. J Biol Chem 275, 27258-
27265. 
www.intechopen.com
 
Acute Phase Proteins: Structure and Function Relationship 
 
59 
Taylor, KE, Giddings, JC, & van den Berg, CW. (2005). C-reactive protein-induced in vitro 
endothelial cell activation is an artefact caused by azide and lipopolysaccharide. 
Arterioscler Thromb Vasc Biol 25, 1225-1230. 
Thompson, D, Pepys, MB, & Wood, SP. (1999). The physiological structure of human C-
reactive protein and its complex with phosphocholine. Structure 7, 169-177. 
Thomas-Rudolph, D, et al. (2007). C-reactive protein enhances immunity to Streptococcus 
pneumoniae by targeting uptake to Fc gamma R on dendritic cells. J Immunol 178, 
7283-7291. 
Thurberg, BL, & Collins, T. (1998). The nuclear factor-kappa B/inhibitor of kappa B 
autoregulatory system and atherosclerosis. Curr Opin Lipidol 9, 387-396. 
Tilg H, et al. (1993) Antiinflammatory properties of hepatic acute phase proteins: 
preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta 
synthesis by human peripheral blood mononuclear cells. J Exp Med 178, 1629-1636. 
Tseng, CF, et al. (2004). Antioxidant role of human haptoglobin. Proteomics 4, 2221-2228. 
Tseng, IC, et al. (2008). Purification from human milk of matriptase complexes with secreted 
serpins: mechanism for inhibition of matriptase other than HAI-1. Am J Physiol Cell 
Physiol 295, C423-C431. 
Valko, M, et al. (2007). Free radicals and antioxidants in normal physiological functions and 
human disease. Int J Biochem Cell Biol. 39, 44-84. 
Van Molle, W, et al. (1999). Activation of caspases in lethal experimental hepatitis and 
prevention by acute phase proteins. J Immunol 163, 5235-5241. 
van Pelt, J, et al. (1996). Carbohydrate-deficient transferrin values in neonatal and umbilical 
cord blood. J Inherit Metab Dis 19, 253-266. 
Verma, S, et al. (2002). Endothelin antagonism and interleukin-6 inhibition attenuate the 
proatherogenic effects of C-reactive protein. Circulation 105, 1890-1896. 
Volanakis, JE, & Wirtz, KW. (1979). Interaction of C-reactive protein with artificial 
phosphatidylcholine bilayers. Nature 281, 155-157. 
Walcheck, B, et al. (1996). Neutrophil-neutrophil interactions under hydrodynamic shear 
stress involve L-selectin and PSGL-1. A mechanism that amplifies initial leukocyte 
accumulation of P-selectin in vitro. J Clin Invest 98, 1081-1087. 
Wang, M, et al. (2009). Novel fucosylated biomarkers for the early detection of 
hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 18, 1914-1921. 
Weiser ,JN, et al. (1998). Phosphorylcholine on the lipopolysaccharide of Haemophilus 
influenzae contributes to persistence in the respiratory tract and sensitivity to 
serum killing mediated by C-reactive protein. J Exp Med 187, 631-640. 
Weiss, SJ. (1989). Tissue destruction by neutrophils N Engl J Med 320, 365-376. 
Whisler, RL, Newhouse, YG, & Mortensen, RF. (1986). C-reactive protein reduces the 
promotion of human B-cell colony formation by autoreactive T4 cells and T-cell 
proliferation during the autologous mixed-lymphocyte reaction. Cell Immunol 102, 
287-298. 
Wiman, B, et al. (1988). Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in 
plasma. FEBS Lett 242, 125-128. 
Williams JP, et al. (1997). Alpha1-Acid glycoprotein reduces local and remote injuries after 
intestinal ischemia in the rat. Am J Physiol 273, G1031-10335. 
Woollard, KJ, Phillips, DC, & Griffiths, HR. (2002). Direct modulatory effect of C-reactive 
protein on primary human monocyte adhesion to human endothelial cells. Clin Exp 
Immunol Today 130, 256-262. 
www.intechopen.com
 
Acute Phase Proteins – Regulation and Functions of Acute Phase Proteins 
 
60
Wong, PS, & Travis, J. (1980). Isolation and properties of oxidized alpha-1-proteinase 
inhibitor from human rheumatoid synovial fluid. Biochem Biophys Res Commun 96, 
1449-1454. 
Xia, D & Samols, D. (1997). Transgenic mice expressing rabbit C-reactive protein are 
resistant to endotoxemia. Proc Natl Acad Sci U S A 94, 2575-2580. 
Xie, L, et al. (2005). C-reactive protein augments interleukin-8 secretion in human peripheral 
blood monocytes. J Cardiovasc Pharmacol 46, 690-696. 
Yang, F, et al. (1995). Cell type-specific and inflammatory-induced expression of 
haptoglobin gene in lung. Lab Invest. 73, 433-440. 
Yang, Z & Hancock, WS. (2005). Monitoring glycosylation pattern changes of glycoproteins 
using multi-lectin affinity chromatography. J Chromatogr A 1070, 57-64. 
Zeller, JM, & Sullivan, BL. (1992). C-reactive protein selectively enhances the intracellular 
generation of reactive oxygen products by IgG-stimulated monocytes and 
neutrophils. J Leukoc Biol 52, 449-455. 
Zhang, WM, et al. (2000). Characterization and determination of the complex between 
prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant 
prostatic diseases. Scand J Clin Lab Invest Suppl 233, 51-58. 
Zhong, W, et al. (1998) Effect of human C-reactive protein on chemokine and chemotactic 
factor-induced neutrophil chemotaxis and signaling. J Immunol 161, 2533-2540. 
Zipfel, PF & Skerka, C. (2009). Complement regulators and inhibitory proteins. Nat Rev 
Immunol  9, 729-740. 
Zouki, C, et al. (1997). Prevention of In vitro neutrophil adhesion to endothelial cells 
through shedding of L-selectin by C-reactive protein and peptides derived from C-
reactive protein. J Clin Invest 100, 522-529. 
Zouki, C, et al. (2001). Loss of pentameric symmetry of C-reactive protein is associated with 
promotion of neutrophil-endothelial cell adhesion. J Immunol 167, 5355-5361. 
www.intechopen.com
Acute Phase Proteins - Regulation and Functions of Acute Phase
Proteins
Edited by Prof. Francisco Veas
ISBN 978-953-307-252-4
Hard cover, 368 pages
Publisher InTech
Published online 03, October, 2011
Published in print edition October, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The two volumes of Acute Phase Proteins book consist of chapters that give a large panel of fundamental and
applied knowledge on one of the major elements of the inflammatory process during the acute phase
response, i.e., the acute phase proteins expression and functions that regulate homeostasis. We have
organized this book in two volumes - the first volume, mainly containing chapters on structure, biology and
functions of APP, the second volume discussing different uses of APP as diagnostic tools in human and
veterinary medicine.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Sabina Janciauskiene, Tobias Welte and Ravi Mahadeva (2011). Acute Phase Proteins: Structure and
Function Relationship, Acute Phase Proteins - Regulation and Functions of Acute Phase Proteins, Prof.
Francisco Veas (Ed.), ISBN: 978-953-307-252-4, InTech, Available from:
http://www.intechopen.com/books/acute-phase-proteins-regulation-and-functions-of-acute-phase-
proteins/acute-phase-proteins-structure-and-function-relationship
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
